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COMPOSITIONS AND COMPOUNDS FOR USE AS

MOLECULAR ADJUVANT FOR A NICOTINE
WACCINE

0001 Pursuant to 35 U.S.C. S.202(c), it is hereby

acknowledged that the U.S. Government has certain rights in
the invention described herein, which was made, in part,
with funds from the National Institutes of Health, grant
numbers CA 57362 and CA 36727.
FIELD OF THE INVENTION

0002 The present invention relates to the field of vac
cines and Stimulation of acquired immunity. In particular,
the present invention provides novel compositions for use as
a nicotine vaccine.
BACKGROUND OF THE INVENTION

0003. The disease consequences of habitual tobacco
Smoking are irrefutable. Smoking tobacco is a well-estab
lished causative factor in the pathogenesis of cancers of the
lung, oral cavity, nasal/sinus cavities, esophagus, and blad
der. Likewise, inhalation of tobacco Smoke is a major
etiologic factor in the expression of airway inflammatory
disorderS Such as chronic obstructive pulmonary disease and
allergic asthma. Smoking is a well-known risk factor for
developing coronary heart disease and Stroke. In addition,
cigarette Smoking contributes to an increase in Systemic
bone loss and an impairment in the ability to heal bone grafts
and fractures. SmokerS have less Strong, leSS healthy, min
eral-deficient bones with reduced bone blood supply and
fewer and leSS functional bone-forming cells compared to
their non-Smoking counterparts. Bone loSS in the oral cavity
asSociated with cigarette Smoking is well documented in the
dental literature. Cigarette Smoking is a major risk factor for
periodontitis and has been directly linked to alveolar bone
loSS, overall tooth loSS, and an impaired healing/fusion of
dental implants.
0004. The adverse health effects associated with tobacco
Smoking also extend to those exposed to Secondary Smoke.
Chronic exposure to Secondary Smoke is a growing public
health problem, which has been directly linked to an
increased incidence of Sudden infant death Syndrome in
infants of mothers who smoke, low birth weight of infants
from mothers who Smoked during pregnancy, middle ear
infections in children, exacerbation of childhood and adult

asthma, bronchitis, lung/nasal cancers, and ischemic heart
disease in children and adults.

0005. As well established as the adverse health conse
quences of Smoking, So too are the health benefits derived
from Smoking cessation. Former Smokers, for example, are
at a significantly lower risk for total mortality in all Smok
ing-related disease categories relative to their Smoking
counter-parts. Moreover, the risk for total mortality among
all disease categories for those who quite Smoking and
maintain compliance eventually reaches a level comparable
to those who never Smoked.

0006 Quitting smoking, however, can be difficult and
even with Support, only a third of the Smoking population is
able to quit. Since tobacco dependence results from an
addiction to nicotine, Strategies aimed at Smoking cessation
target nicotine's addictive effects. The mainstay of these
treatments is nicotine replacement therapy with gradually

Apr. 28, 2005
decreasing doses of nicotine delivered via transdermal
patches, gum, or inhaled nicotine formulations. Although
this approach has proven beneficial to Some individuals, the
continued administration of the principal addictive Sub
stance in cigarette Smoke is not an ideal approach to Smok
ing cessation and the nicotine itself may exert adverse
cardiovascular effects. Nicotine addiction is also treated

with neuroreceptor antagonists/partial agonists to modulate
neurotransmitter pathways in the brain. Since these recep
tors and their Signaling pathways also mediate normal brain
function, Side-effects are common with the use of these

drugs. Thus, there is a growing need for the development of
improved Strategies to help individuals quit Smoking and
maintain long-term compliance in an effort to prevent the
costly and debilitating diseases caused by Smoking.
0007 One innovative approach to Smoking cessation and
long-term compliance is to treat the addictive properties of
nicotine via immunization with a nicotine vaccine. The

rationale to this approach is that nicotine-specific antibodies
generated in response to the vaccine bind circulating nico
tine outside of the central nervous System and reduce drug
access to receptor Sites in the brain. This peripheral Site of
action, along with the high Specificity and affinity of nicotine
antibodies, makes vaccination an attractive therapeutic
approach to Smoking cessation. Also, the use of a nicotine
vaccine has the potential of inducing a “memory' immune
response, wherein anti-nicotine immunity may be invoked
when one in exposed to nicotine, an attractive feature for
ensuring long-term compliance. Moreover, a nicotine vac
cine would be significantly leSS expensive than conventional
treatments for nicotine addiction and Smoking cessation.
0008 Toward that end, drug-specific vaccines have been
used Successfully to attenuate the behavioral/psychoactive

effects of cocaine (Fox et al., (1996) Nature Med. 2:1129
1132), heroin (Killian et al., (1978) Pharmacol. Biochem.
Behav. 9:34-352), and nicotine (Hieda et al., (1997) J.
Pharmacol. Exp. Therap. 283:1076-1081; and Pentel et al.,

(2000) Pharmacol. Biochem. Behav. 65:191-198) in rodent

models. The Success of these applications emanated from the
vaccine’s ability to induce drug-specific antibodies that
bound the drug and limited its distribution to the brain where
the addictive effects are exerted. These anti-drug vaccines
were composed of the drug conjugated to a large carrier
protein and immunizations were performed in the presence
of added adjuvant. The two nicotine Vaccines, for example,

were made by conjugating 6-(carboxymethylureido)-(+)nicotine to keyhole limpet hemocyanin (KLH) (Hieda et al.,
(1997) J. Pharmacol. Exp. Therap. 283:1076-1081) and
trans-3'-aminomethylnicotine to Pseudomonas aeruginosa

expoprotein A (rEPA) (Pentel et al., (2000) Pharmacol.
Biochem. Behav. 65:191-198). Immunizations were per

formed in rabbits and rats in the presence of complete and
incomplete Freund's adjuvant. Under these conditions, both
nicotine vaccines were capable of inducing nicotine-specific
antibodies. These antibodies, when used in passive immu
nizations protocols, were shown to bind plasma nicotine in
rats, which minimized its adverse cardiovascular effects, and
decreased nicotine distribution to the brain, which attenu

ated its psychoactive/behavioral effects. Also, when used in
active immunization protocols, both vaccines generated
nicotine-Specific antibodies that were capable of altering the
plasma and brain concentrations of nicotine in rats.
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0009 While the results detailed above illustrate the thera
peutic potential of a nicotine vaccine for controlling the
addictive properties of nicotine, these approaches do not
provide a viable Strategy for Smoking cessation and long
term compliance. The nicotine-carrier protein designs used
in these Studies, for example, are limited by their inability to
direct the nicotine antigen to and activate antigen presenting

cells (APC), which are essential in processing and present

ing the antigen to helper T cells. Such APC-mediated
engagement of helper T cells is critical for the Thelper cells
to release the cytokines necessary to "help' the antibody
producing B cells generate the antigen-Specific antibodies. A
Second limitation to these vaccine designs is their reliance

0014) Antigen-presenting cells contemplated for target
ing according to the present invention include, but are not
limited to, monocytes, dendritic cells, macrophages, B cells
and some T cells. In preferred embodiments of the invention,
the characteristic determinant on the selected APC is a cell

Surface receptor and the targeting moiety of the APC
targeted antigen is a ligand that binds to the receptor. It is
particularly preferred that the cell Surface receptor be an
immunomodulatory receptor. Suitable cell Surface receptors
include, but are not limited to, C5a receptor, IFNY receptor,

on the use of harsh adjuvants (Such as Freund's) to com

CD21 (C3d) receptor, CD64 (FcyRI) receptor, and CD23
(FcyRII) receptor.
0015. One exemplary APC-targeted antigen of the inven

Full citations for these references are found at the end of the

0020 T-Ag-T (wherein Ag represents a mul

pensate for this lack of APC specificity. These adjuvants
comprise oily Solutions containing components, Such as
lipopolysaccharides that Stimulate generalized immune
responses. A third limitation is the lack of control in attach
ing the nicotine hapten to the carrier protein in a consistent
and reproducible manner. Attachment of a Small hapten like
nicotine to a large carrier protein with many potential
reactive sites allows for the possibility of hapten-to-carrier
ratioS varying from lot to lot, causing variation in vaccine
efficacy. Also, the immunogenic character of the carrier
protein may be altered or diminished by the random attach
ment of large numbers of haptens to immunologically
important Sites.
0010. Accordingly, a need exists for a nicotine vaccine
that is capable of causing Smoking cessation and long term
compliance. The present invention addresses this need by
providing a composition for use as a nicotine Vaccine
comprising a molecular adjuvant that is able to deliver both
Stimulatory Signals and the nicotine antigen to APCs,
thereby inducing an anti-nicotine antibody response with
little or no inflammatory Side-effects and without reliance on
other added adjuvants.
0.011 Several publications are referenced in this applica
tion by numerals in parenthesis in order to more fully
describe the state of the art to which this invention pertains.
Specification. The disclosure of each of these publications is
incorporated by reference herein.
SUMMARY OF THE INVENTION

0012. The present invention provides novel compositions
and methods for delivering Specific antigens to antigen
presenting cells, and Simultaneously delivering Signals to
those cells that produce a desired immune response. The
compositions of the invention are Sometimes referred to
herein as “APC-targeted activating antigens.”
0013. According to one aspect of the invention, these
APC-targeted activating antigens, which elicit an immune
response mediated by an antigen-presenting cell, comprise
at least one antigenic moiety functionally linked to at least
one targeting moiety that binds Specifically to a character
istic determinant on the antigen-presenting cell. For pur
poses of the present invention, the term “functionally
linked' is defined generally as linking of the moieties in Such
a way that each moiety retains its intended function. This is
particularly relevant with respect to the targeting moiety,
which is designed to bind to a characteristic determinant on
the antigen-presenting cell.

tion is designed to bind to the C5a receptor, and the targeting
moiety is a C5a receptor ligand, which is preferably a
peptide analog of C5a corresponding to the C-terminal 10
residues of C5a. Another exemplary composition of the
present invention is designed to bind to the IFNY receptor,
and comprises a targeting moiety which is a IFNY receptor
ligand, preferably a peptide analog of IFNY corresponding to
the N-terminal 39 residues of IFNY.
0016. The antigenic moiety of the APC-targeted antigens
of the invention can comprise essentially any antigenic
Substance, including, but not limited to, peptides and pro
teins, glycopeptides and glycoproteins, phosphopeptides and
phosphoproteins, lipopeptides and lipoproteins, carbohy
drates, nucleic acids and lipids. The APC-targeted antigens
can comprise more than one antigenic moiety, and likewise
can comprise more than one targeting moiety. Moreover,
these moieties can be functionally linked in Several fashions.
For instance, if “T” represents a targeting moiety, and "Ag”
represents an antigenic moiety, the APC-targeted antigens of
the present invention may be oriented as follows:
0017 Ag-T:
0.018 T-Ag:
0019) T-Ag-T;
tiplicity of antigens.
0021 Examples of the general formulas set forth above
include:

0022 Ag-C5a agonist peptide;
0023 IFNY peptide-Ag;
0024 IFNY peptide-Ag-C5a agonist peptide.
0025. According to other aspects of the present invention,
methods are provided for using the APC-targeted antigens of
the invention. These include methods of activating an anti
gen-presenting cell with a targeting ligand and methods of
eliciting an antigen presenting cell-mediated immune
response in a Subject in which Such a response is desired. In
particular, a method is provided to treat or prevent Smoking
addiction by administration of a therapeutic amount of
compositions of the invention. General methods of immu
nizing or Vaccinating a patient requiring Such treatment,
methods of treating a tumor, and methods for producing
antibodies Specific for a pre-determined antigen for use as
research tools or for diagnostic purposes are also contem
plated to be within the Scope of the present invention.
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0026. The numerous features and advantages of the com
positions and methods of the present invention are described
more fully in the detailed description set forth below.
0.027 FIG. 1 is a graph illustrating the antibody titer
produced in mice immunized with the indicated peptide
constructs, as determined by radioimmunoassay, and shows

the relationship between the amount of I-goat anti-mouse

antibody bound vs. the dilution factor of mouse sera which
had been incubated in microtiter wells coated with the

MUC1 epitope peptide.
0028 FIG. 2 is a graph illustrating the increase in anti

body titer in the sera of mice collected either before (pre) or
after immunization with peptides 3 (YKQGGFLGLYSFKP
MPLaR) (SEQ ID NO:2) and 4 (YSFKPMPLaRKQGG
FLGL) (SEQID NO:5) as determined by radioimmunoassay

and shows the relationship between the amount of I-goat
anti-mouse antibody bound and the dilution factor of mouse

Sera which had been incubated in microtiter wells coated

with MUC1 epitope peptide. Note that peptides 3 and 4
comprise two moieties, a targeting ligand and an antigen to
which an immune response is desired.
0029 FIG. 3 is a graph illustrating the titers of antibody
classes and Subclasses produced in mice following immu

nization with peptide 3 (YKQGGFLGLYSFKPMPLaR)
(SEQ ID NO:2) as determined by ELISA using rabbit
anti-mouse IgA, IgG1, IgG2a, IgG2b, IgG3, and IgM,
followed by goat anti-rabbit conjugated to peroxidase and
detected using p-nitrophenyl phosphate cleavage monitored
at 405 nm.

injections at 21 day intervals using 50 lug doses of the

restricted peptide (S-39) was covalently attached directly
to the N-terminus of the C5a agonist (IPOSLDSW
WTSLYSFKPMPLaR; SEQ ID NO: 13), spaced by two Arg
residues (IPQSLDSWWTSLRRYSFKPMPLaR; SEQ ID
NO: 14), or spaced by the furin protease-Sensitive Sequences
RVRR (SEQ ID NO: 19) (IPQSLDSWWTSLRVRRYS
FKPMPLaR; SEQ ID NO: 15). Spleen cell suspensions
were prepared from two mice in each group 14 days fol
lowing the third injection. The cell Suspensions were cul

tured in the presence of the Sasso peptide (75 nM) for four

days and used as effector cells in Cr-release assays against
P815S or P815 targets. Percent specific lysis of Cr-labeled
P815S is shown and represent the means of triplicate deter
minations. Lysis of Cr-labeled P815 cells by these effector

cells was less than 5% at an effector-to-target ratio of 50:1

(not shown).
0033 FIG. 7 is a graph illustrating the antibody reactivity
of the indicated nicotine vaccine construct.

0034 FIG. 8, Panel A depicts the total number of dipper
entries for each treatment regime employed, as indicated and
Panel B depicts the index of learning-evaluation Score for

the first light (before Sucrose is given) for each treatment
regime employed, as indicated.
0035 FIGS. 9 and 10 collectively depict the ability of the
nicotine vaccine to generate nicotine Specific antibodies in
rats immunized with the vaccine.

0030 FIG. 4 is a graph illustrating the specificity of
binding of the antibody Subclasses in Sera from mice immu

nized with peptide 3 (YKQGGFLGLYSFKPMPLaR) (SEQ
ID NO:2) as determined by ELISA using binding to micro
titer wells coated with MUC1 epitope peptide and detection
with rabbit anti-mouse IgG2a, IgG2b, or IgM followed by
incubation with goat anti-rabbit conjugated to peroxidase
and detected using p-nitrophenyl phosphate cleavage moni
tored at 405 nm.

0.031 FIG. 5 is a graph showing the HBSAg-specific CTL
response is induced only by C5-a-active constructs. BALB/c
mice received three S.c. injections at 21 day intervals using

50 ug doses of the HBSAg-LMHC class I restricted peptide

(Sasso) Synthesized with two Arg residues appended to the
C-terminal end (IPOSLDSWWTSLRR, SEQ ID NO: 18),
the double-Arg-linked C5a-active construct (IPOSLDSW
WTSLRRYSFKPMPLaR; SEQID NO: 14) and the double
Arg-linked C5a-inactive constructs (IPQSLDSWWTSLR
SEQ

ID

NO:

17

and

YSFKPMPLaRRRIPQSLDSWWTSL; SEQ ID NO: 16).

Pooled Spleen cell Suspensions were prepared from two mice
in each group 14 days following the third injection. The cell
Suspensions were cultured in the presence of the Sasso

peptide (75 nM) for four days and used as effector cells

against Cr-labeled P815S (HBSAg transfectant) or P815
targets. Percent specific lysis of Cr labeled P815S cells at
various effector to target ratioS is shown and represent the
means of triplicate determinations. Lysis of Cr labeled
P815 cells at an effector-to-target ratio of 50:1 was less than

5% (not shown). The data are representative of three sepa

rate experiments.

Sensitive-linked constructs. BALB/c mice received three S.c.

C5a-active constructs in which the HBSAg-L'MHC class I

BRIEF DESCRIPTION OF THE DRAWINGS

RYSFKPMPLaRG;

0032 FIG. 6 is a graph showing that HBSAg-specific
CTL responses are induced only by the C5a-active, protease

DETAILED DESCRIPTION OF THE
INVENTION

0036) A major obstacle in the development of vaccines
and other immunostimulatory agents is the inability of Some
antigens to be readily taken up and processed by antigen
presenting cells. Uptake of antigens by APCS is an essential
Step for Stimulating an effective immune response, Since the
immune System recognizes the antigen only after it has been
processed by the APC and presented on the surface of the
APC in conjunction with the major histocompatibility com

plex (MHC).
0037. It is known that APCs, including dendritic cells,

monocytes, macrophages and B cells, possess functional
receptors for numerous molecules that modulate the immune
response. It has now been discovered in accordance with the
present invention that ligands which bind to these receptors
can be conjugated to weakly immunogenic antigens for
example, as a way of delivering antigens to the antigen
presenting pathway of the APC and Simultaneously activat
ing the antigen presenting capacity of the APC. Thus, these
conjugates bind to a receptor on the APC Surface, transduce
a biological Signal, and are internalized by the APC. The
antigenic moiety of the conjugate is thereby delivered to the
antigen presenting pathway of the APC along with the
simultaneous activation of the APC.

0038. The above-described conjugates are sometimes
referred to herein as “molecular adjuvants” or “APC-tar
geted activating antigens.” The APC-targeted activating
antigens of the invention are designed to elicit immune
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responses mediated by one or more types of antigen pre
Senting cells. Accordingly, an APC-targeted activating anti
gen comprises at least one antigenic moiety linked to a
targeting and activating moiety that binds Specifically to at
least one characteristic determinant on the Selected antigen
presenting cell type. This binding is followed by internal
ization of the APC-targeted antigen and results in presenta
tion of the antigen moiety on the surface of the APC. For
purposes of the present invention, the term “antigenic moi
ety' may refer to any Substance to which it is desired that an
immune response be produced. The Selected antigenic moi
ety may or may not be capable of eliciting an immune
response by conventional means.
0039. The term “determinant” is used herein in its broad
Sense to denote an element that identifies or determines the

nature of Something. When used in reference to an antigen
presenting cell, “determinant’ means that Site on the antigen
presenting cell which is involved in Specific binding by the
targeting ligand moiety of the molecular adjuvant of the
invention.

0040. The expression “characteristic determinant’ as
used herein, Signifies an epitope (or group of epitopes) that
Serves to identify a particular population of antigen present
ing cells and distinguish it from other antigen presenting cell
populations. Cell-associated determinants include, for
example, components of the cell membrane, Such as mem
brane-bound proteins or glycoproteins, including cell Sur
face antigens, histo-compatibility antigens or membrane
receptors.

0041. The expression “specific binding”, as used herein
refers to the interaction between the targeting ligand moiety
and a characteristic determinant on the antigen presenting
cell population Sought to be activated in accordance with
this invention, to the Substantial eXclusion of determinants

present on other cells.
0.042 Certain exemplary compositions of the invention
have been Synthesized, and have been shown to elicit
APC-mediated immune responses in accordance with the
mechanisms described above. For example, antigenic
epitopes have been conjugated to the amino-terminal end of
a C5a decapeptide agonist capable of binding to C5a recep
tors present on the Surface of many APCs. Mice that were

inoculated with an epitope of human MUC1 (a cell Surface
associated mucin) conjugated to Such a C5a agonist exhib

ited pronounced antibody titers against the MUC1 epitope,
including high titers of Specific antibodies with isotypes

IgG2a and IgG2b. Mice that were inoculated with (1) MUC1
epitope alone, (2) C5a agonist alone, (3) unconjugated
MUC1 epitope and C5a agonist together, or (4) C5a agonist
conjugated to MUC1 epitope in a manner in which the
biological activity of the C5a moiety was blocked, did not
express a significant Specific immune response. These
results are described in greater detail in Example 1. Similar
results were observed with conjugates of C5a agonist to a 12

kDa polypeptide, Serum amyloid A (SAA), as described in

greater detail in Example 2. In addition, Example 6 depicts
the results of the C5a agonist conjugated to various nicotine
constructs. These data tend to demonstrate the feasibility of
the invention, which is to use receptor-binding ligands as a
way to deliver antigens to APCs, with the simultaneous
activation of APCs by the ligand moiety.
0043. As described in greater detail below, the C5a
receptor is only one of many receptors expressed on APCs.

This invention encompasses the use of various ligands with
Selectivity to other receptors that mediate Signal transduction
events in the APCs, to be used alone or in conjunction with
C5a agonists to influence the nature of immune response
generated, i.e., humoral, cellular, Th1, Th2, and the like.
Vaccines and other immunotherapeutic agents can be pre
pared with an array of Such targeting moieties that Serve to
target the antigen moiety to a Specific population of APCs
and Simultaneously activate these and other cells involved in
various immune modulatory pathways.
0044) The detailed description below sets forth preferred
embodiments for making and using the targeted antigens of
the present invention. To the extent that Specific compounds
and reagents are mentioned, these are for the purposes of
illustration, and are not intended to limit the invention. Any
biochemical, molecular or recombinant DNA techniques not
Specifically described are carried out by Standard methods,
as generally Set forth for example, in Ausubel et al., “Current
Protocols in Molecular Biology,” John Wiley & Sons, Inc.,
1995.

0045 I. Preparing APC-Targeted Activating Antigens
0046 A. Selection of Components
0047 Antigen presenting cells have various receptors on
their Surfaces for known ligands. Binding of ligands to these
receptorS results in Signal transduction events that Stimulate
immune or tolerance responses. Many of these receptors are
known to internalize and recycle in the cell. Others are
Suspected of doing the same. AS Such, these receptors are
ideal targets for delivering antigens and activation signals
simultaneously to APCs.
0048 AS discussed above, APCs include several cell
types including macrophages, monocytes, dendritic cells, B
cells, Some T cells and other poorly characterized cell types.
It is believed that these different classes of APCs can

produce different types of immune responses. Accordingly,
by targeting a receptor prevalent on a Specific population of
APCs, a particular desired immune response may be
favored. An exemplary list of receptors contemplated for
targeting in the present invention, and the rationale for their
selection, is set forth below. These APC receptors are
particularly appropriate for use in the present invention
based on the following criteria: they are receptors expressed
on APCS; the receptors are internalized upon binding of
ligand; the receptors can transmit Signals in the cells that
influence antigen processing and presentation by these cells,
Some of the receptors are believed to be involved in Signal
ing Th1 type cellular responses, whereas others are predicted
to generate Th2 type humoral responses. The list Set forth
below is not exhaustive, but merely representative of the
type of targeted receptors preferred in practicing the present
invention. Other receptors, or other cell-Surface character
istic determinants on antigen presenting cells may also be
used as targets for the targeted antigens of the present
invention. The receptor or other characteristic determinant
need not be directly involved in the immune response.
0049 C5a receptor. This receptor is preferred for use
according to the present invention. It is present on PMNs,
macrophages, dendritic cells, Smooth muscle cells and Some
mast cells. A number of biological activities have been
ascribed to C5a, mostly associated with inflammatory and
immune responses. According to a preferred embodiment,
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this invention relies on the capability of C5a, as a targeting
ligand, to Specifically bind to its cognate receptor, So as to
activate antigen presenting cells, including macrophages,
monocytes and dendritic cells, through a G protein-mediated
Signal transduction pathway. Subsequent to Signal transduc
tion, the receptor/ligand complex is internalized. In the case
of dendritic cells, C5a has been shown to induce a Th1 type
response.

0050. IFNY receptor. The interferon Y receptor is
expressed on macrophages, monocytes, dendritic cells, other
APCs, some B cells, fibroblasts, epithelial cells, endothe
lium, and colon carcinoma cells. IFNY binding to its receptor
induces macrophage and dendritic cell activation, B cell
differentiation, and expression of MHC class I and class II
molecules in many cell types. The receptor is involved in
Signal transduction pathways. IFNY is mainly produced in
the body by activated T cells, particularly during the gen
eration of Th1 type response. It is also produced by CD8+
cytotoxic T lymphocytes following recognition of antigen
associated with MHC class I and by natural killer cells

stimulated with TNFC. and microbial products (Barclay et al.
1993.).
0051 CD 21 (C3d receptor). CD 21 is the receptor for the

C3d complement fragment. It is a receptor for the Epstein
Barr virus and may be an important interferon C. receptor

(Barclay et al., Supra). CD 21 is expressed on B cells,

follicular dendritic cells, other APCs, pharyngeal and cer
Vical epithelial cells, and Some thymocytes. It is involved in
activation and proliferation of B cells through a signal
transduction mechanism and it has been associated with

increases in antigen presentation activities by those cells.

0.052 CD 64 (FcyRI receptor). CD 64 is a high affinity
receptor for IgG, the only known receptor that binds mono

meric IgG (Barclay et al., Supra). This receptor is found on

macrophages, monocytes and other immune cell populations
treated with IFNY. The IgG binding site resides in the CH2
domain. IFNY Strongly upregulates expression of this recep
tor, which is the primary receptor involved in antibody
dependent cell mediated cytotoxicity reaction, and phago
cytic activity by these cells.

0053 CD (Fce RII receptor). CD23 is a low affinity
receptor for IgE (not related to the high affinity IgE receptor
found on basophils and mast cells). It is found on some B

cell populations, macrophages, eosinophils, platelets, and

dendritic cells (Barclay et al., Supra). CD 23 mediates IgE

dependent cell mediated cytotoxicity and phagocytosis by
macrophages and eosinophils, and binding of IgE immuno
complexes increases the efficiency of antigen processing and
presentation by Some ACPS, through a signal transduction
mechanism that includes the p59 fyn tyrosine kinase. The
ligand for CD 23 is the Ce3 domain of IgE.
0.054 As mentioned above, the APC-targeted antigens of
the present invention comprise at least one antigenic moiety
and at least one targeting moiety. The targeting moiety can
be derived from naturally-occurring ligands for a Selected
receptor on an APC, or analogs and derivatives of Such
ligands. For instance, the C5a receptor is a preferred recep
tor for use in practicing the present invention. Naturally
occurring C5a can be utilized as the targeting moiety in the
APC targeted activating antigens of the invention. However,
native C5a is not preferred for use as the targeting moiety as
it induces a myriad of pro-inflammatory responses which

may be undesirable Side effects. In particularly preferred
embodiments of the invention, C-terminal C5a agonist ana
logs capable of C5a receptor binding and Signal transduction
in a response Selective manner are utilized. Such analogs are
described in detail in U.S. Pat. Nos. 5,96,230 and 5,942,599

to SanderSon et al., and commonly-owned U.S. application
Ser. No. 08/299,285, the entire disclosure of which is

incorporated by reference herein.
0055 An exemplary C5a C-terminal decapeptide agonist
preferred for use in the present invention is:
YSFKPMPILaR

(SEQ ID NO: 1)

0056. This decapeptide is a potent agonist of naturally
occurring C5a, and is preferred to naturally occurring C5a
because its Small Size contributes to ease of Synthesis and
solubility. Moreover, these conformationally biased peptides
are stable toward Serum carboxypeptidase digestion, eXpress
level biological selectivity, and have been shown to be
non-toxic in high concentrations in athymic mice.
0057 Peptide analogs of naturally-occurring interferon Y
are also contemplated for use in the present invention.
Peptides corresponding to the amino terminal 39 amino
acids of IFNY have been shown to compete for binding with
native IFNY. Antibodies against this domain block biological
activity, and removal of the first 10 amino terminal residues
eliminates biological activity. This Suggests that binding of
IFNY to its cognate receptor is mediated by this portion of
the molecule. Accordingly, peptides based on this domain
are contemplated to be of use for delivering antigens to
APCs expressing IFNY receptors. In this regard, it should be
noted that human and mouse IFNY are absolutely species
Specific in binding and activity. Consequently, for Stimulat
ing APC-mediated immune responses in mice, the mouse
peptides will be utilized, and the human peptide will like
wise be utilized for stimulating APC-mediated immune
responses in humans. The mouse IFNY 39 amino acid
peptide analog is composed of the following Sequence:
HGTVIESLESLNNYFNFFGIDWEEKSLFLDIWRNWQKDG

(SEQ ID NO : 3)

0058. The human IFNY 39 amino acid peptide analog is
composed of the following Sequence:
QDPYWKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEE

(SEQ ID NO : 4)

0059 Another ligand contemplated for use in the present
invention is the C3dG component of complement. This
component is a 348 residue fragment derived by proteolytic

cleavage from the C3b precursor (residue 955-1303 of C3;
Swissprot accession p01024). C3dG can be converted to
C3d (residues 1002-1303) and C3g (residues 955-1001).

C3dG and C3d remain associated with non-activator Sur

faces and Serve as opSonins for phagocytosis by macroph
ages and other antigen presenting cells. Cd 21 is the C3dG
and C3d receptor.
0060. The above-listed ligands exemplify the type of
ligand preferred for practice of the present invention. How
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ever, it will be appreciated by those skilled in the art that
other ligands may be utilized as the targeting moiety of the
APC-targeted antigens of the invention. These include
ligands that are already known in the art, as well as ligands
that may be discovered and developed henceforth. Antibod
ies or antibody fragments also may be used to target APC
Specific cell Surface antigens.
0061 The type of antigen that can be chosen as the
antigenic moiety in the present invention can be any peptide,
polypeptide or derivative thereof for which an immune
response on antibody production is desired. These include

but are not limited to, peptides, polypeptides (i.e. proteins)
and derivatives thereof, Such as glycopeptides, phosphopep
tides and the like. Synthetic peptide and polypeptide deriva
tives or analogs, or any other Similar compound that can be
conjugated to a receptor-targeting moiety can be used in the
present invention. Moreover, these peptides, proteins and
derivatives may comprise Single epitopes or multiple
epitopes for generating different types of immune responses.
Indeed, if an entire protein is conjugated to a targeting
moiety, this protein is likely to comprise numerous epitopes,
which may vary depending upon the Solvent conditions and
their effect on Secondary and tertiary Structure of the protein.
Carbohydrates, nucleic acids and other non-protein Sub
stances also may be used as the antigenic moiety. Methods
are available in the art for conjugating these Substances to
the peptide or protein targeting moiety.

0.062 Other Substances that can be used as the antigenic
moiety include Small molecules, Such as (1) metabolic
byproducts (especially those that are toxic); (2) various
environmental toxins or irritants (e.g., aromatic hydrocar
bons, asbestos, mercury compounds and the like); (3) drugs
(e.g., cocaine, heroin, nicotine, etc.) for treating addiction;
and (4) venoms from Snakes, Spiders, or other organisms.

Many of these kinds of Small molecules are non-antigenic or
weakly antigenic, So would be appropriate candidates for
use in the present invention. Example 6 below illustrates the
use of nicotine as the antigenic moiety.
0.063. In preferred embodiments of the invention, the
antigenic moiety comprises agents that are weakly antigenic
or non-antigenic under currently available immunization
conditions. For example, nicotine falls into this category
because it is a Small organic compound that is non-antigenic
under normal conditions. Equally, many tumor-associated
antigens fall into this category, because the antigens are also
expressed by normal cells. Therefore, immunological toler
ance to Such molecules makes it difficult to Stimulate

responses against Such antigens. Other proteins that fall into
this category include naturally occurring proteins form one

Species (e.g., human) for which it would be desirable to

produce antibodies in another Species but which are recal
citrant to antibody generation in the other species.
0.064 One well-characterized tumor antigen is a cell
Surface-associated mucin that is highly overexpressed and
differentially glycosylated by different adenocarcinomas,
including breast, pancreas, lung and prostate carcinomas.
Aberrant glycosylation of MUC1 by adenocarcinomas
results in the addition of Some blood group carbohydrate
antigens to this core protein and the exposure of epitopes
which have been detected by monoclonal antibodies on the
core protein that are not exposed on forms of this protein
produced by normal epithelial cells. A full-length cDNA

Sequence of human mucin-1 (MUC1) revealed an encoded
protein with an average length of approximately 1200 amino
acids (depending on the length of the tandem repeat allele)
with Several obvious domains: an amino terminal Signal
peptide; a large domain made up of multiple identical 20
amino acid tandem repeats flanked by Several repeats that
contain degenerate Sequences, a hydrophobic-spanning
domain of 31 amino acids, and a cytoplasmic domain of 69
amino acids at the carboxyl terminus. The most well
characterized tumor associated epitopes described to date for
MUC1 are found in the tandem repeat domain. These
include carbohydrate Structures and protein Structures.
MUC1 tumor associated epitopes are well characterized, and
thus have been proposed to be used for the production of
tumor vaccines using conventional methods. Exemplary
compositions of the present invention comprise MUC1
epitopes, Such as those Set forth below, as the antigenic
moiety of the APC-1 targeted antigens of the invention, to
demonstrate the potential of the present invention as potent
tumor vaccines.

0065. MUC1 epitope predicted to bind class I molecules

of the H-2K' type has sequence homology to the juxtamem
brane region of MUC1;
YKQGGFLGL

(SEQ ID NO: 6)

0066 MUC1 tandem report has the sequence:
GWTSAPDTRRAPGSTAPPAH

(SEQ ID NO: 7)

0067. The components comprising the APC-targeted
antigens of the invention can be made Separately, then
conjugated. For example, a Small peptide analog, Such as the
above-described C5a agonists, may be produced by peptide
Synthetic methods, and conjugated to a protein which has
been purified from naturally occurring biological Sources.
Alternatively proteins engineered for expression via recom
binant methods may be used. Additionally, targeted antigens

comprising peptide components (i.e., a peptide antigenic
epitope conjugated to a peptide receptor ligand) can by

Synthesized in tandem by peptide Synthetic chemistry
according to known methods and as described in greater
detail below. Finally, targeted antigens of the invention

comprising two larger polypeptide moieties (i.e., a large
polypeptide antigen linked to a large ligand) can be made by

recombinant techniques. For example, DNA molecules
encoding both components can be ligated together by
recombinant means, then expressed as the conjugated fusion
protein. Methods of making these different types of com
positions are Set forth in greater detail below.
0068 B. Peptides
0069 Oligopeptides required for the present invention
may be prepared by various Synthetic methods of peptide
Synthesis via condensation of one or more amino acid
residues, in accordance with conventional peptide Synthesis
methods. Preferably, peptides are Synthesized according to
Standard Solid-phase methodologies, Such as may be per
formed on an Applied Biosystems Model 430A peptide

Synthesizer (Applied BioSystems, Foster City, Calif.),

according to manufacturer's instructions. Other methods of
Synthesizing peptides or peptidomimetics, either by Solid
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phase methodologies or in liquid phase, are well known to
those skilled in the art. When solid-phase synthesis is
utilized, the C-terminal amino acid is linked to an insoluble

resin Support that can produce a detachable bond by reacting
with a carboxyl group in a C-terminal amino acid. One
preferred insoluble resin Support is p-hydroxymethylphe

noxymethyl polystyrene (HMP) resin. Other useful resins

include, but are not limited to: phenylacetamidomethyl

(PAM) resins for synthesis of some N-methyl-containing
peptides (this resin is used with the Boc method of solid
phase synthesis; and MBHA (p-methylbenzhdrylamine) res

ins for producing peptides having C-terminal amide groups.
0070. During the course of peptide synthesis, branched
chain amino and carboxyl groupS may be protected/depro
tected as needed, using commonly-known protecting
groups. In a preferred embodiment, NC.-amino groups are
protected with the base-labile 9-fluorenylmethyloxycarbo

nyl (Fmoc) group or t-butyloxycarbonyl (Boc groups). Side
chain functional groups consistent with Fmoc Synthesis may
be protected with the indicated protecting groupS as follows:

arginine (2,2,5,7,8-pentamethylchroman-6-sulfonyl); aspar
agine (O-t-butyl ester); cysteine glutamine and histidine
(trityl); lysine (t-butyloxycarbonyl); Serine and tyrosine
(t-butyl). Modification utilizing alternative protecting

groups for peptides and peptide derivatives will be apparent
to those of skill in the art.

0071 C. Proteins
0.072 Full-length proteins for use in the present invention
may be prepared in a variety of ways, according to known
methods. Proteins may be purified from appropriate Sources,
e.g., human or animal cultured cells or tissues, by various
methods Such as gel filtration, ion eXchange chromatogra
phy, reverse-phase HPLC and immunoaffinity purification,
among others. However, due to the often limited amount of
a protein present in a Sample at any given time, conventional
purification techniques are not preferred in the present
invention.

0073. The availability of nucleic acids molecules encod
ing a protein enables production of the protein using in Vitro
expression methods known in the art. For example, a cDNA
or gene may be cloned into an appropriate in vitro transcrip
tion vector, such a pSP64 or pSP65 for in vitro transcription,
followed by cell-free translation in a suitable cell-free trans
lation System, Such as wheat germ or rabbit reticulocytes. In
Vitro transcription and translation Systems are commercially
available, e.g., from Promega Biotech, Madison, Wis. or
BRL, Rockville, Md.

0.074 Alternatively, according to a preferred embodi
ment, a Selected peptide or protein may be produced by
expression in a Suitable procaryotic or eucaryotic System.
For example, a DNA molecule, encoding a peptide or
protein component of the invention, or an entire composite
targeted antigen of the invention, may be inserted into a
plasmid vector adapted for expression in a bacterial cell,
Such as E. coli, or into a baculovirus vector for expression
in an insect cell. Such vectors comprise the regulatory
elements necessary for expression of the DNA in the host
cell, positioned in Such a manner as to permit expression of
the DNA in the host cell. Such regulatory elements required
for expression include promoter Sequences, transcription
initiation Sequences and, optionally, enhancer Sequences.
0075) A peptide or protein produced by gene expression
in a recombinant procaryotic or eucaryotic System may be

purified according to methods known in the art. In a pre
ferred embodiment, a commercially available expression/
Secretion System can be used, whereby the recombinant
protein is expressed and thereafter Secreted from the host
cell, So as to be readily purified from the Surrounding
medium. If expression/Secretion vectors are not used, an
alternative approach involves purifying the recombinant
protein by affinity Separation, Such as by immunological
interaction with antibodies that bind specifically to the
recombinant protein. Such methods are commonly used for
isolating peptides and proteins.
0076 D. Linking Separately-Made Proteins and/or Pep
tides

0077. In an alternative embodiment, protein and/or pep
tide components of the invention are Synthesized Separately,
then conjugated using Standard methods known by those
skilled in the art. For example, a Synthetic peptide may be
chemically coupled to a protein using m-maleimidobenzoyl

N-hydroxysuccinimide ester (MBF). This reagent cross
links amino- and carboxy-terminal thiol groups in the pep
tide with lysine Side chains present in the protein.
Alternatively, a Synthetic peptide may be coupled to a
protein using glutaraldehyde, a common croSS-linking agent.
Another methods for chemically coupling a peptide to a

protein is through the use of carbodiimide and 1-(3-dim
ethylaminopropyl)-3-ethylcarbodiimide methiodide (EDC).
AS described in greater detail in Example 2, this method was
used to conjugate a C5a C-terminal decapeptide analog to

serum anyloid A (SAA). Methods for joining two proteins

together are also available.
0078. The peptides or proteins of the invention, prepared
by the aforementioned methods, may be analyzed according
to Standard procedures. For example, they may be Subjected
to amino acid Sequence analysis, mass spectra analysis or
amino acid compositional analysis according to known
methods.

0079

E. General Formulae and Exemplary Compositions

of the Invention

0080. The APC-targeted antigens of the invention can
comprise one or more antigenic moieties, and likewise can
comprise one or more targeting moieties. Moreover, these
moieties can be functionally linked in Several ways. For
instance, if “T” represents a targeting moiety, and "Ag”
represents an antigenic moiety, the APC-targeted antigens of
the present invention may be organized as follows:
0081 Ag-T:
0082 T-Ag:

0083) T-Ag-T;
0084 T-Ag-T (wherein Ag represents a mul

tiplicity of antigens,
0085 Examples of the general formulas set forth
above include:

0086 Ag-C5a agonist peptide;
0087 IFNY peptide-Ag;
0088) IFNY peptide-Ag-C5a agonist peptide.
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0089. Other representative compositions of the invention
include:

0090 MUC1 Class I binding epitope -C5a agonist
C-terminal peptide
0091 Murine or human IFNY peptide-MUC1
Class I binding epitope
0092 Murine or human IFNY peptide-MUC1 tan
dem repeat
0093 MUC1 Class I epitope-C3dG peptide
0094 SAA-K-Ahx-C5a C-terminal peptide (Ahx=
eamino hexanoic acid).
0.095. It will be appreciated by persons skilled in the art
that the APC-targeted activating antigens of the invention
may be adapted for inclusion of large or complex antigens.
This may be accomplished, for example, by inclusion of a
“spacer” (Such as the K-AhX Spacer moiety in the exemplary
compound above) between the antigen and the targeting
moiety. Such chemical modifications are familiar to bio
chemists.

0.096 Cleavable linkers. In addition to the foregoing sorts
of Spacers and linkers, it has also been discovered in
accordance with the present invention that introduction of a
cleavage-prone oligopeptide between the targeting moiety
and the antigen can improve the immunogenicity of the
molecule. For instance, as described in greater detail in
Example 5, an Arg-Arg dipeptide or an Arg-Val-Arg-Arg

(SEQ ID NO: 19) tetrapeptide between the C5a peptide
analog, YSFKPMPLaR (SEQ ID NO: 1) and a cytotoxic T
lymphocyte (CTL) epitope of hepatitis B virus surface
antigen was found to robustly elicit a CTL response to the
antigen in mice, in the absence of added adjuvant. The
Arg-Arg dipeptide adds a Scissile bond that is Susceptible to

cleavage or cleavage by trypsin-like proteases (e.g., Subtili
sin). The Arg-Val-Arg-Arg (SEQ ID NO: 19) tetrapeptide
imbues Sensitivity to cleavage by furin (another trypsin-like
protease). While not intending to be limited by an particular
explanation of the underlying mechanism by which the
robust CTL response was elicited, it is believed that the

Arg-Arg or Arg-Val-Arg-Arg (SEQ ID NO: 19) protease

Sensitive linker peptides facilitate cleavage of the molecular
adjuvant within the APC, thereby more expeditiously free
ing the antigen for further processing and presentation of the
APC cell Surface.

0097. Other scissile bond dipeptides or other oligopep
tides also can be inserted between the targeting moiety and
the antigen. These include residues to create a peptide

bond(s) that is Susceptible to other cytoplasmic proteases or

proteases found within any of the intracellular antigen
processing organelles. Preferred Sites comprise dibasic

dipeptides (i.e., various dipeptide permutations comprising
Arg, Lys or His) or oligopeptide cleavage sites for the

trypsin family or proteases.
0.098 Another option is the creation of a dipeptide scis
Sile bond that is Susceptible to acid-catalyzed hydrolysis
when exposed to the acidic conditions typically found within
intracellular endoSomal/lysosomal compartments of an anti

gen presenting cell (APC). In addition, other epitope-target

ing moiety linkages are contemplated to have a similar
utility in the efficiency of processing by APCs. These
include Sequences that are known or Suspected to facilitate

or enhance 1) the transport/update of epitope constructs into
the rough endoplasmic reticulum (RER), 2) the association
of epitope to MHC class I and/or class II determinants, 3)
transport of epitope through the cis, medial, and trans Golgi
apparati, and 4) entry into transport vehicles associated with
MHC class I.

0099 Thus, a variety of “cleavable linkers” can be
inserted between the targeting moiety and the antigen to
facilitate processing of the antigen by the antigen-presenting
cells. As used herein, the term “cleavable linker” refers to

any linker between the antigenic moiety and the targeting
moiety that promotes or otherwise renders the molecular

adjuvant more Susceptible to cleavage (by proteases, low pH

or any other means that may occur within or around the

antigen-presenting cell) and, thereby, processing by the

antigen-presenting cell, than an equivalent molecular adju
Vant lacking Such a cleavable linker.
0100 II. Uses of APC-Targeted Activating Antigens
0101 The APC-targeted activating antigens of the
present invention have broad potential for clinical applica
tions in humans and animals. AS discussed above, a signifi
cant impediment to the development of vaccines and other
immunotherapeutic agents is the apparent inability of par
ticular antigens to be readily taken up and processed by
antigen presenting cells. The compositions of the invention
facilitate the Specific delivery of an antigen to a population
of antigen presenting cells, whereupon the delivery mecha

nism (e.g., using as the targeting moiety a receptor ligand
capable of transducing a biological signal) simultaneously

activates the antigen presenting pathway. of the APC. Thus,
the present invention enables development of vaccines and
other immunothereapeutics that can Specifically target any
peptide antigen or other antigenic Structure covalently
attached to a ligand for a receptor present on an antigen
presenting cell. It is believed that antigens linked to ligands
that Selectively bind to and activate a particular population
of APCs can not only generate an immune response, but can
influence the nature of the immune response that is gener
ated. Thus, immune responses that favor antibody, cellular,
Th1 or Th2 responses, respectively, may be Selectively
generated. Vaccines may also be developed with an array of
Such targeting moieties thereby Serving to target a Selected
antigen or antigens to Several populations of APCs and
Simultaneously activate these and other cells involved in
various immune modulatory pathways.
0102) The ability to generate either antibody or cell
mediated immune responses against different specific anti
gens has broad general applicability, and it is anticipated that
the APC-targeted antigens of the invention will be extremely
useful for these purposes. For example, antibody responses
have been shown to be capable of protecting against differ
ent Viral or bacterial infection, and antibodies are known to

inactivate different toxins or toxic compounds that may
affect the well being of humans or animals. Different cell
mediated immune responses can provide protection against
Viral or other intracellular pathogens, and can play a role in
Some anti-tumor responses. It is believed that different
antigen presenting cells and the context in which these cells

are stimulated to present antigen (co-stimulation mediated
by different ligand-receptor interactions) are important fac
torS determining the nature of the above responses.
0103) The targeted antigens of the present invention
should find particular utility in the development of active

Apr. 28, 2005

US 2005/0O89524 A1

Specific immunotherapeutic agents (i.e., cancer “vaccines”)
based on cancer-associated antigens. For example, it has
been hypothesized that induction of Strong cell-mediated

immune responses (involving Th1 cells and/or cytotoxic T
lymphocytes) would provide the most effective protection

against various forms of cancer. A vaccination Strategy
utilizing the APC-targeted antigens of the invention can be
designed to induce this type of response. In this regard, it is

known that stimulation with some cytokines (IL-12, IFNY)

can induce predominantly Th1 type responses over Th2 type
responses for certain antigens.
0104. As a step toward developing anti-cancer Vaccines
for clinical use, the compositions of the invention can be
used to advantage as research tools to further explore the
effect of stimulating a certain population of APCs with a
tumor antigen and determining the effect on an anti-tumor
immune response. To this end, it should be noted that the
present application exemplifies targeted antigens comprising
an epitope of a particular tumor-specific antigen, Mucin-1.
0105 Previous tumor vaccine formulations that aim to
immunize patients with compounds that are identical to
compounds already produced by tumors have proven to be
of limited value, probably because tumors that progreSS have
been Selected for their lack of immunogenicity in their

respective host (e.g., the host is tolerant to existing tumor
antigens). Thus, one important challenge of producing effec

tive tumor vaccines is generating reagents that counteract
immunological tolerance to tumor-associated antigens. One
purpose of the APC-targeted antigens described above is to
induce in the immunized individual a is response against

antigen comprising SAA conjugated to a C5a peptide ligand
produced a significant antibody response in mice injected
with the conjugated molecule. In a Similar fashion, targeted
antigens comprising any Weakly-antigenic or non-antigenic
component of interest could be made and used to produce
Specific antibodies in laboratory animals, for use as immu
nodiagnostic reagents.
0107 Antibodies for use as immunotherapeutic agents
can also be generated using the compositions of the inven
tion. AS one example, there has been a great deal of recent
interest in developing reagents capable of down-regulating
or inhibiting the complement cascade to modulate local and
Systemic inflammatory responses. To this end, the C3a
convertase, which is active early in the cascade, could
provide an ideal target for complement inhibition. C3a
convertase cleaves the peptide C3 into two components, C3a
and C3b, and therefore must be able to access the cleavage
site on C3 in order to accomplish the result. Antibodies
directed toward the C3a-C3b cleavage site are expected to
be effective in blocking access of C3a convertase to the
cleavage Site, thereby inhibiting this early Step in the
complement cascade. Such antibodies may be generated
using a targeted antigen of the invention comprising, as the
antigenic moiety, the short peptide Sequence comprising the
C3a/C3b cleavage Site. The Sequence could then be conju
gated to an appropriate targeting moiety, Such as the C5a
C-terminal decapeptide agonists exemplified herein. Thus,
the compositions would be useful to generate an immuno

therapeutic agent (e.g., an antibody that blocks the activity
of C3a convertase) for treating an adverse inflammatory

their tumor that is similar to that Seen in individuals under

condition.

going allograft rejection. In other words, the goal is to
induce an autoimmune reaction against the tumor that is
capable of destroying the tumor. The immunological param
eters that regulate tolerance to tumor antigens are not well
understood; nonetheless the compositions described herein
have the potential to counteract this tolerance and thus
induce Specific immune responses that mediate tumor rejec

0108) III. Nicotine Vaccine.
0109. In a particularly preferred use, as stated above, the
compositions of the invention may be utilized to treat the
addictive properties of nicotine addiction via immunization
with a nicotine vaccine. The rationale to this approach is that
nicotine-Specific antibodies generated in response to the
vaccine bind circulating nicotine outside of the central
nervous System and reduce drug access to receptor Sites in
the brain. This peripheral Site of action, along with the high
Specificity and affinity of nicotine antibodies, makes vacci
nation an attractive therapeutic approach to Smoking ceSSa
tion. Also, the nicotine vaccine has the potential of inducing
a “memory immune response, wherein anti-nicotine immu
nity may be invoked when one in exposed to nicotine, an
attractive feature for ensuring long-term compliance.
0110 Toward that end, the composition employed as a
nicotine vaccine may comprise any molecular adjuvant
described herein linked to a nicotine hapten in any manner
described herein. Typical embodiments of Such composi
tions include the following:

tion.

0106 The targeted antigens of the present invention will
also find broad utility in the production of antibodies for use
as immunodiagnostic and immunotherapeutic agents. For
immunodiagnostic purposes, antibodies are widely used in
various quantitative and qualitative assays for the detection
and measurement of biological molecules associated with
diseases or other pathological conditions. For reasons that
often are not well understood, it is sometimes difficult to

generate antibodies against certain biological molecules
using conventional means. The compositions of the present
invention provide an alternative means for inducing an
animal to produce antibodies against a weakly-antigenic or
non-antigenic Substances. The utility of the compositions of
the invention in this regard is shown clearly in Example 2,
below, in connection with Serum amyloid A. The appearance
and abundance of this protein in the body is Strongly
correlated with Systemic inflammatory StreSS, which is a
condition that is very difficult to quantitate. It is believed that
quantitative assays for SAA levels would be an excellent
indicator of general, Systemic inflammation; therefore it
would be of benefit to generate antibodies against the protein
in a non-human Species. This protein has proved particularly
recalcitrant to the generation of antibodies using conven
tional measures. AS described in Example 2, a targeted

(a) Nic-YSFKPMPLaR (Nic-SEQ ID NO: 1);
(b) Nic-YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID NO: 2);
(c) Nic-YKQGGFLGLRRYSFKPMPLaR (Nic-SEQ ID NO: 20);
(d) Nic
YKGGFLGLYSFKPMPLaR (Nic-SEQ ID NO:2);
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-continued

(e) Nic
YKQGGFLGLRRYSFKPMPLaR (Nic-SEQ ID NO:20 );
(f) Nic
Nic-YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID NO: 2); and
(g) Nic
Nic-YKQGGFLFLRRYSFKPMPLaR (Nic-SEQ ID NO: 20).

0111. In one embodiment, the nicotine vaccine comprises
composition (a) above and is the molecular adjuvant
YSFKPMPLaR (SEQ ID NO:1) covalently modified on the

N-terminal end with a nicotine hapten. In yet another
embodiment, the nicotine vaccine comprises any one of

compositions (b)-(g) and is composed of the B cell epitope
from the juxta-membrane region of MUC1 (YKQGG
FLGL)(SEQ ID NO:6) modified with nicotine at the N-ter
minus of the peptide and/or the C-amino moiety of the
indicated Lys residue. In vaccine compositions (c), (e), and
(g) the nicotine-modified B cell epitope is separated with the
protease-Sensitive, dibasic Arg-Arg (RR) Sequence. In yet
another exemplary embodiment, the nicotine vaccine com
positions detailed in Example 6 may be employed.
0112 i. Peptide Synthesis and Nicotine Attachment. Oli
gopeptides required for the present invention may be pre
pared by various synthetic methods of peptide synthesis via
condensation of one or more amino acid residues, in accor

dance with conventional peptide Synthesis methods. In one
preferred embodiment, as more generally described above,
the peptides may be Synthesized by Standard Solid phase
orthogonal methods in which the reactive Side-chain groups
of the residues are protected with acid-labile groupS and the
amino group of each reside is protected with the base-labile

9-fluorenylmethoxycarbonyl (Fmoc) group. In this method,

Synthesis begins with the fully protected C-terminal residue
attached to an insoluble resin Supported via its carboxyl
group. The Fmoc group of this first residue is deprotected
with base, thereby exposing only the amino group for a
coupling reaction with the carboxyl group of the Second

provided by the side-chains of Asp or Glu residues. These
residues can come from either the naturally occurring resi
dues in the Sequence or they can be added Specifically for
this reason during the course of peptide Synthesis by any
generally known method.
0114. After its synthesis, the resin-attached, fully pro
tected, nicotine-modified peptide is then Subjected to mild
acidolysis to remove the Side-chain protecting groupS and
cleave the peptide from the resin according to Standard
methods. All peptides may then be purified by preparative
and analytical reverse-phase HPLC according to generally
known methods and characterized by amino acid composi
tional analysis and mass Spectrometry.
0115 ii. Modification of Nicotine. Given the ease with
which free amino and carboxyl groups can be generated at
various sites on the peptide as detailed above, one method of
attaching nicotine haptens to the peptide is via the formation
of an amide bond provided that the nicotine molecule is
modified So that it presents the complementary carboxyl or
amino groups. An amide bond linkage between nicotine and
the peptide is attractive because it maintains the same type
of covalent linkages that already exist in the peptide, thus
minimizing the possibility of introducing new immunogenic
character to the antigen of interest or directing immunogenic
recognition away from the antigen of interest.

0116. Accordingly, in one embodiment, nicotine may be

modified to express the complementary carboxyl or amino
groups necessary for amide linkage to the peptide by the
Synthetic routes described below. These routes will generate
the carboxyl and amino groups on different Sites of the
nicotine molecule, which allows the opportunity of conju
gating nicotine to various Sites on the peptide Such that
different potential antigenic regions of the nicotine molecule
can be exposed and presented.
0117 The nicotine haptens, NH1 and NH2, described in
Sections a. and b. below each express carboxylic acid
functional groups to allow amide bond formation with either
the N-terminal or LyS e-amino groups of the peptide.

amino acid residue to form an amide (peptide) bond between
the first and Second residues. The Fmoc group on the Second
residue may be deprotected with base exposing this resi
due's amino group for reaction with the carboxyl group of
the third residue. This cycle of deprotection and coupling is
repeated until the full peptide Sequence is completed. A final
deprotection of the last Fmoc group with base exposes the
peptide's N-terminal amino group and all other reactive
Side-chain groups in the peptide remain protected. This free,
N-terminal amino group may then Serve as at least one site

NH1
HOOC

to which a nicotine molecule can be attached via an amide

linkage when the nicotine molecule is modified to provide
the complementary carboxyl group as detailed below.
0113. In yet another embodiment, synthesis of the peptide
is performed Such that it provides carboxyl groups for
nicotine attachment via an amide linkage when the nicotine
molecule is modified to provide the complementary amino
group as detailed below. Any one of the free amino groups
generated by the above route on the protected peptide can be
converted into a carboxyl group by reaction with, for
example, Succinic anhydride or any other appropriate
reagent. Other free carboxyl groups on the peptide could be

N

CH

NH2

21

N

N

s

N

N-cool
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with NaBH, resolution with (+)-MTPA, and reductive
debromination with hydrogen and palladium on carbon

-continued

affords (S)-nor-nicotine (5). In yet another embodiment, 5

HN-N
21

w xx

can be obtained in an enantio-Selective Synthesis Starting
with a chiral 2-hydroxy-3-pinanone ketimine. Treatment of
5 with B-propiolactone in hot acetonitrile will afford NH2.

y

X

N

CH
Nicotine hapten (NH) strucutures showing the location of the
carboxyl and amino functional groups for linking to the peptide
SCHEME 2

0118 a. NH1: Carboxyl Modification of the pyridine
Ring of Nicotine. As shown in Scheme 1 below, in one
embodiment, the synthesis of NH1 begins with treatment of

Br

NN

21

commercially available ethyl-5-bromo-nicotine (1) with

a, b, c

21

N

1-vinylpyrrolidinone anion followed by acid-catalyzed
decarboxylation and ring closure to give 5-bromomyOSmine

w

-

y

N
N

N
2

(2). Reduction of 2 with NaBH/CBZ-D-proline followed by

N-methylation and resolution with dibenzoyl-L-tartaric acid

will provide (S)-5-bromonicotine (3). Coupling of 3 with
ethyl acrylate followed by Sequential hydrogenation and
ester hydrolysis will yield NH1.
SCHEME 1.
O

B

21

N

OEt

a, b

Br

N

21

N

N
1.

N

c,d,e

Br

21

N

N

w

-

y
CH

N
3

2

HOOC

EtOOC

21
N
N

s

g, h
CH

21
CH

N
4

Key: (a) LiNCTMS)2, N-vinylpyrrollidinone; (b) MIC1, A; (c) NaBH4, CBZ-D-proline; (d) HCHO, HCOOH, A; (e) dibenzoyl-L-tartaric
acid: (f) ethyl acrylate, Pd(OAc); PPh3. K2CO3: (g) H2, 10% Pd C: (h) methanesulfonic acid.

0119). In yet another embodiment, NH1 may be prepared
by first converting 3 to its iodo derivative, (S)-5-iodonico

-continued

tine, via hexa-n-butylditin and a catalytic amount of tetraki

S(triphenyl-phosphine)palladium followed by iodostannyla
tion with iodine monochloride. In a further embodiment,

21

3. This intermediate is then employed in a palladium cata

s

NH1 can synthesized by producing (S)-5-ethylnicotine from

lyzed coupling with ethyl chloroformate (52) to form the

alkyne ester. AS described above, Sequential hydrogenation
and ester hydrolysis of the alkyne ester yields NH1.
0120 b. NH2: Carboxyl Modification of the Pyrrolidine
Nitrogen of Nicotine. As shown in Scheme 2 below, the
synthetic intermediate 2 described above will serve as the
starting material for the synthesis of NH2. Reduction of 2

N

Nuco
NH2

Key: (a)NaBH4; (b) (+)-MTPA; (c) H2.10% Pd C; (d) B-propiolactone, A.

0121. In still a further embodiment, the conversion of 5
to NH2 is performed by conjugate addition of 5 to ethyl
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acrylate followed by ester hydrolysis. Reductive alkylation
of 5 with NaBH, and hydroxyacetic acid is another potential
method to generate NH2.
0122) c. NH3: Amino Modification of the Pyroline Ring
of Nicotine. As shown in Scheme 3 below, synthesis of NH3
may begin by treatment of the commercially available
pyridine-3-carboxaldehyde with methylamine to form the
imine. Treatment of the imine with Succinic anhydride in

boiling xylene affords trans-1-methyl-4-carboxyl-5-(3-py
ridyl)-2-pyrrolidone (7). Esterification and Subsequent
lithium aluminum hydride (LAH) reduction affords trans
3'-hydroxymethylnicotine (8). The final three steps in the

synthesis of NH3; i.e., tosylation of alcohol 8, conversion to
the azide, and azide reduction by LAH may be performed
according to any generally known method. In yet another
embodiment, NH3 may be formed by conversion of 7 to its
4-carboxamide followed by an LAH reduction of both
lactam and carboxamide functional groups.
SCHEME 3
HOOC
O

w

Crs
N

--

21y
s

O c, d

--

CH

6

7
HO

hapten other than the methods set forth above may be
utilized. In addition, it will also be appreciated by the is
skilled artisan that methods other than those detailed above

for attaching the nicotine hapten to the peptide may be
employed.
0.125 The following examples are provided to describe
the invention in further detail. These examples are intended
to illustrate the invention in greater detail. They are not
intended to limit the invention in any way.
EXAMPLE 1.

Evaluation of Mucin Epitope (MUC1/C5a Agonist)
Conjugate for Recruitment and Activation of

Antigen Presenting Cells (APCs) and Stimulation
of an Immune Response in Mice
0.126 The C5a receptor is present on numerous antigen
presenting cells, including monocytes, macrophages, den
dritic cells, and other cell types. In this example, a composite
peptide comprising a mucin epitope (MUC1) functionally
linked to a decapeptide agonist analog of C5a corresponding
to the C-terminal effector region of the natural favor was
evaluated for its ability to activate the APCs thereby stimu
lating an immune response in mice. This evaluation is based
on the known property of C5a receptors to internalize and
recycle in the antigen presenting cell, thereby acting as ideal
candidates for delivering antigens to and Simultaneously
activating Signals in the APCs. Because C5a receptors are
particularly common on macrophages, monocytes and den
dritic cells, it is believed that the use of a C5a agonist analog
to bind C5a receptors will result in preferential activation of
these APCs.

21

N

N

CH

N
8

fg
HN

0127 i. Abbreviations. Except where noted, the single
letter designation for the amino acid residues is used: alanine
is A, arginine is R; asparagine is N, aspartic acid is D;
cystine is C; glutamine is Q; glutamic acid is E.; glycine is
G; histidine is H, isoleucine is I; leucine is L.; lysine is K,
methionine is M.; phenylalanine is F; proline is P; serine is
S; threonine is T; tryptophan is W.; tyrosine is Y; and valine
is V. Upper case letters represent the L-amino acid isomer
and lower case the D-isomer.

0128 ii. Peptide synthesis, Purification and Characteriza
tion. The following peptides were Synthesized according to
Standard Solid-phase methodologies on an Applied BioSys

Key: (a) CH3NH2, 3 A molecular sieves: (b) succinic anhydride, A; (c) MeOH,
H2SO4 (cat.); (d) LAH; (e) TosCl, Et3N: (f) NaN3, DMF, A; (g) LAH.

0123 d. NH Characterization. The nicotine haptens NH1,
NH2, and NH3, all reaction intermediates, and starting
materials may be purified by distillation, crystallization, or
flash column chromatography. These molecules may then be
purified by analytical and semi-preparative HPLC and struc

ture/composition confirmed by H and 'C NMR, infrared

Spectroscopy, optical rotation, melting point, elemental
analysis, and mass Spectrometry or any other generally
known method.

0.124. It will be appreciated by the skilled artisan that any
number of variations for preparing the peptide or nicotine

tems (Foster City, Calif.) model 430 A peptide synthesizer
and characterized as previously described (7):
0129 (1) The antigenic “juxta-membrane” (JM)
epitope of the human mucin-1 (MUC1), YKQGG
FLGL (SEQ ID NO:6):
0130 (2) The C5a C-terminal decapeptide agonist
analog, YSFKPMPLaR (SEQ ID NO:1);
0131 (3) The composite peptide YKQGGFLGLYS
FKPMPLaR (SEQ ID NO:2), in which the JM

epitope is positioned toward the amino terminus and
the C5a peptide is positioned toward the carboxyl
terminus; and

0132 (4) The composite peptide YSFKPM
PLaRKQGGFLGL (SEQ ID NO:5), in which the JM

epitope of MUC1 is positioned toward the carboxyl
terminus and the C5a analog is positioned toward the
amino terminus.
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0.133 Peptide 3 retains C5a biological activity, whereas
peptide 4 does not because the biologically important car
boxyl terminal end of the C5a analog is blocked by the
presence of the mucin epitope. AS Such, peptide 4 Serves as
a control to determine the importance of the C5a biological
activity to the effectiveness of these peptides for immuni
Zation purposes.
0134) Syntheses were performed on a 0.25 mmol scale on

O-hydroxymethylphenoxymethyl polystyrene (HMP) resins
(0.88 med/g Substitution). N'-amino groups were protected
with the base-labile-9-fluorenylmethyloxycarbonyl (Fmoc)
group. Side-chain functional groups were protected as fol

lows: Arg (Pmc or 2,2,5,7,8-pentamethylchroman-6-sulfo
nyl); Asp (Ot-butyl ester); Cys, Gln & His (Trt or trityl); Lys
(Boc or t-butyloxycarbonyl); Ser & Tyr (t-butyl). Synthesis

was initiated by the in Situ coupling of the C-terminal

residue (N'-Fmoc-L-Arg(Prmc)) to the HMP resin in the
presence of excess N-N'-dicyclohexylcarbodiimide (DCC)
and 1-hydroxybenzotriazole (HOBT) with 4-dimethylami
nopyridine (DMAP) as a coupling catalyst. Peptide chain
elongation was accomplished by repetitive Fmoc deprotec
tion in 50% piperidine in NMP followed by residue coupling

in the presence of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetram
ethyluronium hexafluorophosphate (HBTU).
0135 Side-chain deprotection and cleavage from the

resin were achieved in a single Step acetolysis reaction by
Stirring the peptide-resin in a Solution of 84% trifluoroacetic

acid (TFA), 6% phenol, 2% ethandithiol, 4% thioanisole,

and 4% water for 1.5 hr at room temperature. Free peptide
was precipitated from this Solution by adding cold diethyl
ether. The mixture was filtered through a Scintered glass

Buchner funnel (medium porosity) and the peptide/resin

washed twice with cold ether to remove the thiol Scavenger.
The peptide was extracted by Swirling the peptide/resin in
the funnel with 20-30 ml aliquots of 10% acetic acid
followed by filtration. The extraction aliquots were com
bined, frozen and lyophilized to yield the powdered form of
the crude peptide.
0.136 Peptides were purified by preparative and analyti
cal reverse-phase HPLC on columns packed with Cs
bonded silica. The details of this procedure have been

described by (4). All peptides were characterized by amino

acid compositional analysis and fast atom bombardment

mass spectrometry (FAB-MS).
0.137 iii. Animal Models. The strains of mice used for

this example were inbred females 6 to 12 week old

C57Bl6(H-2) and Balb/c (H-2), which were obtained from

Jackson labs (Bar Harbor, Me...). These two strains which

differ in H-2 haplotypes, were used in this example to
demonstrate that the observed antibody response were not a
result of the Selection or creation of an unique immunogenic
epitope characteristic of the Sequence of the proteins of the
MHC class I and class II molecules important for antigen
processing in one mouse Strain or another. The MUC1
peptide Selected for these Studies contained a motif that may

bind to the H-2K molecule of the C57B16 mice; therefore,

a Strain of mouse that lacked this class I molecule binding

motif (Balb/c) was also studied to determine the relative

contribution of the class I binding motif to the antigen
presentation properties of these peptides.
0138 iv. Immunization protocol. Preimmune sera were
obtained from mice, which were Subsequently immunized

intraperitoneally with 100 lug of the indicated peptide with

RIBI adjuvant (MPL+TDM+CWS) (Sigma Immunochemi
cals). Animals were boosted twice at two week intervals
using the same injection procedure. Sera were obtained
following three immunizations (at 6 weeks).
0.139 v. Analysis of serum antibody responses. For radio
immunoassay (RIA), anti-peptide antibodies were deter
mined, before and at different time points after immuniza

tion, in 96-well microtiter plates (Dynatech Laboratories,
Inc.). Plates were coated with 50 ul of a 100 tug/ml appro
priate peptide in phosphate-buffered saline (PBS) pH 7.4
solution overnight at 4 C. The wells were blocked by
incubation with 5% dry milk in PBS pH 7.4 for at least two
hours. Anti-peptide antibody titers were determined using
serial dilutions of Sera. The Sera were diluted with PBS

containing 0.05% Tween-20, pH 7.4 (washing buffer) and 50
All of each dilution was incubated at 37 C. for 1 hour. The
wells were then drained, washed 4 times with PBS-Tween

and 50 ul of 'I-goat anti-mouse Ab (1-2x10 cpm/well)

was added and incubated for 1 hr at 25 C. After washing,
Specific radioactivity was recorded in a gamma counter
(1272 CliniGamma, LKB).
0140 Anti-peptide antibody isotype titers were deter
mined by enzyme-linked immunosorbent assay (ELISA)
carried out in 96-well microtiter plates. The plates were
coated with 100 tug/ml of appropriate peptide in PBS, pH
7.4, and incubated overnight. The wells were blocked with
5% dry milk in PBS pH 7.4 for at least two hours. Anti
peptide titers were determined using Serial dilutions of Sera
as described above. After the plates were washed 4 times, 50
All of a 1:100 dilution of rabbit anti-mouse IgA, IgG1, IgG2a,
IgG2b, IgG3 and IgM (Zymed) was added to each well and
incubated at 25 C. for 1 hour. The plates were washed 4
times with washing buffer and 50 ul of 1:500 goat anti-rabbit
conjugated to peroxidase (Zymed) was incubated at 37 C.
for 1 hour. Again, the plates were washed 4 times with
washing buffer and bound enzyme was detected by the
addition of 50 til 1 mg/ml p-nitrophenyl phosphate (Sigma)
in 10% diethanolamine (Sigma) pH 9.4. The reaction was
stopped by the addition of 50 ul of 0.5 M Sodium hydroxide
and absorbance values (Alos) were determined on Titertek
Multiskan (Flow Laboratories, Irvine, Scotland).
0141 vi. Experimental groups. Experimental groups
were as follows:

0142 Group A. mice immunized with peptide (1)
0143 Group B. mice immunized with peptide (2)
0144) Group C. mice immunized with peptide (1)
plus peptide (2)
0145 Group D. mice immunized with peptide (3)
0146 Group E. mice immunized with peptide (4).
0147 The results of the experimental protocols are set
forth in FIGS. 1 and 2. As can be seen in the Figures, the
mice in Groups A, B, C and E produced no appreciable
increase in antibody response to inoculation with MUC1

epitope (Group A), C5a agonist peptide (Group B) MUC1

epitope combined with, but not conjugated to, C5a agonist

peptide (Group C), or MUC1 epitope conjugated to the C5a
agonist peptide at its C-terminus, rather than its N-terminus
(thereby blocking C5a biological activity) (Group E). Only
mice inoculated with the MUC1 epitope/C5a agonist peptide
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conjugate of the present invention (Group D) generated an

appreciable antibody response. Furthermore, this stimula
tion was significant. It is clear from these results that
inoculation with the conjugated MUC1 epitope/C5a agonist
peptide was far more efficient in Stimulating a general

immune response (i.e., production of antibodies) than was
inoculation with either peptide alone, or both peptides
together, but not conjugated, or peptides conjugated in the
opposite orientation.
0.148. There are several significant conclusions that can
be drawn based on these results. The fact that both Balb/c

and C57B16 mice showed antibody responses to peptide 3
Suggests that the antigen presenting effect is not restricted by
MHC haplotype. The fact that immune responses were not
produced to peptide 4, or to mixtures of peptide 1 and 2, but
that Substantial responses were produced to peptide 3, Sug
gest that the effect is mediated by the C5a moiety of the
peptide and that the immune response results from the
Simultaneous delivery of antigen peptide and C5a mediated
activation signals to antigen presenting cells.
014.9 The isotypes of the anti-peptide antibodies pro

duced in the immunized mice were determined (FIG. 3) and

were found to consist of IgM, IgG2a, and IgG2b. This
Suggests that the immunogenic peptide is producing T
cell-dependent responses, which generally require antigen
processing and presentation. Data presented in FIG. 4 show
that the antibody response to peptide 3 includes a high
percentage of antibodies that are specific for the MUC1
epitope that was antigen moiety of these Studies.
EXAMPLE 2

Evaluation of Serum Amyloid A/C5a Peptide
Conjugates for Recruitment and Activation of APCs
and Stimulation of Immune Response in Rats
0150 Serum amyloid A is an acute-phase stress response
protein generated by the liver. Along with other acute phase
proteins, SAA is Secreted in response to Systemic inflam
matory StreSS as a protective measure. SAA is of interest
because it appears to be an excellent indicator of general,
Systemic inflammation, which is a phenomenon that is very
difficult to quantitate. Because serum levels of SAA have
been observed to parallel the rise and fall of the systemic
inflammatory response, quantization of Serum levels of this
peptide would provide an effective means of assessing
inflammation. One way to accomplish this is to develop
antibodies against SAA that could be used for quantitation
Such as in an ELISA assay. However, SAA has been par
ticularly recalcitrant to the generation of antibodies against
it. In this example, an evaluation was made of the ability of

SAA conjugated to a C5a C-terminal analog (as described in
Example 1) to activate antigen producing cells and produce

an antibody response in rats.
0151 i. Production and preparation of proteins and pep
tides. The C-terminal C5a analog K-AhX-YSFKPMPLaR

(SEQ ID NO:8) (AhX is aminohexanoic acid, which is a
linear aliphatic spacer moiety) was produced as described in

Example 1. The aliphatic Spacer moiety was included to
Separate the critical receptor-binding C5a analog from the
bulky protein to be attached to the amino terminus.
0152 Serum amyloid A was conjugated to the C5a pep

tide analogs according to the following method. SAA (100

pig) was reacted with a 50-fold molar excess of a water
soluble carbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl
carbodiimide methiodide (EDC), in 200 ul of phosphate
buffered saline, pH 7.5, at room temperature for 30 minutes.

A 50-fold molar excess of the peptide (K-Ahx-YSFKPM
PLaR) (SEQID NO:8) and a 100-fold molar excess of a base
diisopropylethylamine (DIEA) were added to this solution.
Water was added to the solution to bring the reaction mixture
to a volume of 400 ul. This solution was stirred overnight at
room temperature and then lyophilized to a dry powder. The
powder was diluted to the appropriate Volume with water to
generate the Stock mixture used for inoculating the animals.
0153 ii. Experimental protocols. Rats were injected
intraperitonealy with an inoculant comprising the SAA/C5a
peptide conjugates in phosphate-buffered Saline with or
without RIBI adjuvant. Booster injections were given two
and five weeks after the initial injections. The rats were
Sacrificed Seven weeks after the initial injection and anti
mucin antibody production was assessed from the Serum
titers, as described in Example 1.
0154) Significant anti-SAA antibody was produced from
both groups of rats, whether or not RIBI adjuvant was
included in the inoculation. AS Visualized by gel electro
phoresis and autoradiography of anti-SAA antibody eluted
from the plate assays, it appeared that anti-SAA antibody
titers were essentially equivalent, or slightly higher, in rats
inoculated with SAA/C5a peptide conjugate in the absence
of RIBI adjuvant as compared to the same inoculation
without the adjuvant. Thus, antigenic conjugates comprising
the C5a peptide analog are useful for generating antibodies
against large proteins, as well as against Smaller peptide
fragments, Such as those described in Example 1. Moreover,
the Successful generation of anti-SAA antibodies utilizing
this method is particularly promising for purposes or pro
ducing antibodies against weakly- or non-antigenic peptides
or proteins.
EXAMPLE 3

Production and Characterization of Site-Directed

Neutralizing Antibodies Specific for a Peptide

(KR(33-52) from the Predicted Amino-Terminal

Region of the Human Kappa Receptor
O155 Receptors for human opioid peptide hormones
have been described on numerous cell types. The receptors
for u, K and 6 ligands have recently been cloned from
genomic and cDNA libraries derived from normal tissue and
cell lines. Considerable homology exists among the u, K and
Ö receptors, except for the N-terminal regions of the recep
tors. The N terminal region of the human kappa receptor

(amino acid residues 1-100) is relatively hydrophilic and

would be predicted to be exposed on the surface of the cell

membrane. A 20 residue peptide KRG3-52)), was chosen
antibody (5).
0156 The method of production of a polyclonal antise

and used to raise a Site directed peptide Specific polyclonal
rum in rabbits using the molecular adjuvant, C5a-agonist
peptide conjugated to the KR epitope is Set forth below. The
binding Specificity and biological activities of the resulting
polyclonal antiserum raised to the predicted extracellular

region of the human kappa receptor (KR) are also described

below.
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O157 i. Construction of Targeted-Immunogen. A peptide
construct consisting of the KR(33-52) (FPGWAEPDSNG
SAGSEDAQL) (SEQ ID NO:9) covalently attached to the
N-terminal end of a conformationally biased, C5a comple
ment fragment agonist analogue peptide (YSFKPMPLaR)
(SEQ ID NO: 1) was synthesized according to the methods
in Example 1 and as previously reported (7).
0158 ii. Preparation of anti-KR(33-52) Antiserum and
Peptide-Specific ELISA. Rabbits were immunized s.c. with
500 ug of FPGWAEPDSNGSAGSEDAQLYSFKPMLaR

(SEQ ID NO:10) construct in complete Freund's adjuvant
(GIBCO, Grand Island, N.Y.) on day 0 followed by booster

injections on days 30 and 60 in incomplete Freund's adju
vant. Serum was collected starting 75 days after the initial
immunization.

0159. The presence of anti-peptide antibody was deter
mined by using a peptide Specific ELISA utilizing the free

KR(33-52) peptide as previously described (8). Anti-KR(33
52) and normal rabbit Y-globulin (RGG) were purified by
protein A Sepharose chromatography (Sigma) (8) prior to
Sc.

0160 iii. Cells and culture conditions. The neuroblas
toma cell SK-N-SH (HTB 11), ductal breast cell carcinoma
T47D (HTB 133), Jurkat T cell leukemia, (TIB 152), U937
histolytic lymphoma (CRL1593), THP1 human monocyte
(TIB 202), EBV-transformed B cells SKW 6.4 (TIB 215)
and CESS (TIB 190) (American Type Culture Collection,

Rockville, Md.) were cultured in DMEM or RPMI 1640

supplemented with 10% fetal calf serum, 25 mM HEPES, 1
mM L-glutamine, 2 mM Napyruvate, 50 Upenicillin and 50
tug/ml Streptomycin. The human neuronal precursor cells

NT2 (Stratagene, La Jolla, Calif.) were cultured in Opti
MEM (Gibco) supplemented as above. All cultures were
incubated at 37° C. in a humidified chamber with 7.5% CO.
0.161 Peripheral blood derived mononuclear cells were
obtained from healthy male and female Volunteers, isolated
by Ficoll-Hypague" density gradient centrifugation and
enriched for macrophage by adherence to plastic.
0162 iv. Flow Cytometry. Single-color flow cytometry

analysis of cells (1x10") in PBS containing 1% bovine calf
Serum and 0.1% Sodium azide (staining buffer) were prein
cubated 30 minutes at 4 C. in the presence of 20% normal
human serum. The cells were washed and incubated with

anti-KR(33-52) or RGG for 30 minutes at 4 C., washed and
labeled with PI-conjugated donkey (Fab") fragments of
antirabbit IgG (Zymed, S. San Francisco, Calif.) for 30
minutes at 4 C. (8). For dual color analysis FITC-conju
gated anti-CD3 or anti-CD14 (Pharmingen, San Diego,

Calif.) were also included in the second step. Cells (1x10")

were analyzed on a FACScan (Becton Dickinson, Mountain
View, Calif.) and data were analyzed with the Cell Quest
software as previously described (8).
0163 v. Measurement of cell proliferation. Peripheral
blood mononuclear cell (PBMC) were pulsed on day 2 of

culture with H-thymidine and 18 hours later the cells

harvested on glass fiber filters and processed for Scintillation
counting. Experiments were performed three times and each
Sample done in triplicate.
0164 vi. Measurement of IgG Secretion. Relative IgG
levels in culture Supernatants were determined by indirect

ELISA as previously described (9). Supernatant derived
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from PBMC cultures were collected after 10 days and
assayed for the presence of IgG. Numbers represent the
mean CPM+/-SD from triplicate samples. Experiments
were performed at least three times.
0.165 vii. Characterization of Anti KR Peptide Antiserum.

Serum from rabbits immunized with the KR(33-52) YSFP
MPLaR (SEQ ID NO:10) construct and normal rabbit serum
were assayed for the ability to recognize plate bound KR(33
52) (SEQ ID NO:9) in ELISA. The results show that serum
from rabbits immunized with the KR(33-52) YSFPMPLaR
(SEQ ID NO:10) construct bound free KR(33-52) peptide
(SEQ ID NO:9) in a dose dependent fashion. The titer was
approximately 105. In contrast, Serum from unimmunized
rabbits failed to bind this peptide. Serum samples from
immunized and unimmunized rabbits were Subjected to
protein A-Sepharose chromatography and the column elu

ates were assessed for KR(33-52) (SEQ ID NO:9) specific

antibody. The results indicate that protein A-purified anti

body derived from rabbits immunized with the KRG3-52)
YSFPMPLaR (SEQ ID NO:10) construct binding to free
KR(33-52) (SEQ ID NO:9) was detectable at antibody

concentrations less than 0.1 ng/ml. In contrast, RGG failed
to bind the free peptide. The results from multiple bleedings
indicated that the EDso titer ranged between 1-10 ng/ml.

These results indicate that rabbits immunized with KR(33
52) YSFPMPLaR (SEQ ID NO:10) contained high titer,
KR(33-52) peptide specific antibody.
0166 viii. Binding of anti-R (33-52) antibody to cells

expressing human KR. To determine whether the polyclonal

anti-KR(33-52) antibodies bound to cells expressing the KR,

a variety of mononuclear cells lines and normal human
mononuclear cells were first assayed for the presence of the
K receptor specific mRNA by RT-PCR. RNA samples iso
lated from neuronal cell lines NT2, U937, Jurkat, T47D,

normal human PBMC, and enriched human macrophage
were subjected to RT-PCR analysis with 5' sense and 3'
antisense primerS Specific for the 3' region of the cloned KR
and B-actin. All of the cell lines or cell fractions, except for
the T47D cell line, were positive for the K-receptor specific
PCR product, as expected based on the primer Sequences

used (5).
0.167 Experiments were performed to determine whether
anti-KR(33-52) bound to cells expressing KR specific
mRNA. The results of single color flow cytometric analysis
for several cell lines are shown in Table 2. Flow cytometric
measurements were conducted with human cell lines repre

sentative of macrophage (U937), T lymphocytes (Jurkat),
and B lymphocytes (SKW 6.4 and CESS). The results
indicate that anti-KR(33-52) bound all three cell types.
Anti-KR(33-52) bound to U937 cells to the greatest extent
(MFI-231) compared to normal RGG (MFI-38). As used
herein MFI refers to mean fluorescence intensity. Compari

son of anti-KR(33-52) and RGG binding to the Jurkat line
indicated approximately a 3-fold shift in MFI (MFI =18 vs.
MFI=6). Similar results were obtained with the two B
lymphocyte-like cell lines (SKW 6.4 and CESS). Compari
son of anti-KR(33-52) and RGG binding to the SKW 6.4 line
indicated approximately a 3-fold shift in MFI (MFI =19 vs.
MFI=6). The neuronal cell line was also specifically bound
by the anti-KR(33-52) as indicated by a 3-fold shift in the

MFI over the RGG. Finally, based on the lack of expression
of KR-specific mRNA from the human breast carcinoma cell

line (T47D), this cell line was assessed for its ability to bind
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to anti-KR(33-52) by flow cytometric analysis. The lack of
a KR expression on T47D cells was confirmed by the fact

that anti-KR(33-52) and RGG bound to these cells in an
almost identical fashion. As a positive control, anti-KR(33
52) and RGG were assessed for their ability to bind to an
additional human macrophage-like cell line (THP1). Com
parison of anti-KR(33-52) and RGG binding to this cell line
resulted in a significant shift in MFI (MFI-190 vs. MFI=8).
These results confirm the specificity of anti-KR(33-52) for
the human KR.

Mean

Channel Intensity

RGG

anti-KR Ab

NT2

Neuronal

9

19

U937
Jurkat
SKW 6.4

Macrophage
T-lymphocyte
B-lymphocyte

38
6
6

231
18
19

CESS
Controls

Human breast

&10
-3

&10
-3

8

190

T47D (negative) Carcinoma

THP1 (positive)

Macrophage

ducted with the T cell mitogen PHA. Anti-KR(33-52) was

also able to neutralize the ability of U50,488H to suppress

mitogen-induced T cell proliferation. U50,488H (10 M)

anti-KR(33-52). Preincubation of PBMC with normal RGG

Selected cell type binding of anti-KR(33-52)
antibodies produced in rabbits immunized with C5a-agonist
peptide conjugated to the KRG33-52) sequence as assessed
by single channel color flow cytometric analysis.
Cell Type

contrast, identical concentrations of normal RGG failed to

inhibit KR Selective agonist mediated immunosuppression.
0170 Since SAC has been shown to induce both Tand B
lymphocyte proliferation, Similar experiments were con
suppressed PHA-induced T cell proliferation by 85%. This
Suppression was reversed by preincubating the cells with

TABLE 1.

Cell Line

neutralize U50,488H-mediated suppression of SAC-induced
lymphocyte proliferation in a dose dependent fashion. In

0168 Analysis of intact human PBMC indicated that

these cells express mRNA for a “K-like" R (5). Dual color
flow cytometric analysis was utilized to assay for the bind
ing of anti-KR(33-52) to normal human macrophage
(CD14+) and T lymphocytes (CD3+). It was observed that
both macrophage and T lymphocytes bound anti-KR(33-52)
antibody. Anti-KR(33-52) and RGG were assessed for bind
ing to CD14+ PBMC. The results indicate that anti-KR(33
52) bound CD14+ cells with a 15-fold increase compared to
normal RGG (MFI-320 vs. MFI=21). Anti-KR(33-52) was
also found to bind CD3+ cells (MFI-19 vs. RGG MFI=3)
albeit less than CD14+ cells. These results indicate that
anti-KR(33-52) binds normal PBMC-derived mononuclear
cells as well as mononuclear cell lines, which express
KR-specific mRNA.
0169 ix. Neutralization of U50,488H-mediated Suppres

sion of lymphocyte proliferation by anti-KR(32-52) antibody

in vitro. The results of published studies have shown that
opioid peptide-induced regulation of in Vitro immune
responses can occur via Specific receptor-ligand interactions.
More specifically, it has been shown that the KR-selective
agonist U50,488H is capable of suppressing SAC-induced

lymphocyte proliferation by human PBMC cultures (6). The
inhibition of lymphocyte activation by U50,488H has also
been shown to be reversed by the KR-Selective antagonist

nor-BNI. To determine whether anti-KR(33-52) was capable

failed to block U50,488H-mediated suppression of T cell
proliferation.

0171 Anti-KR(33-52) does not appear to directly modu

late lymphocyte proliferation. The co-culture of PBMC with

anti-KR(33-52), in the absence of mitogen, failed to stimu
late the cells above the media control. Moreover, the com

bination of anti-KR(33-52) and PHA or SAC did not result
in increased cell proliferation compared to PBMC cultures
receiving mitogen only.
0172 X. Neutralization of U50,488N-mediated suppres

sion of IgG synthesis by anti-KR(32-52) antibody in vitro. In

addition to lymphocyte proliferation, U50,488H is a potent
inhibitor of SAC-induced IgG synthesis in human PBMC

cultures (6). To determine whether anti-KR(32-52) was
capable of neutralizing the Suppression of IgG Synthesis,

PBMC were preincubated with anti-KR(32-52) followed by
the addition of U50,488H and SAC, and IgG levels mea

sured on day 10. Results indicate that U50,488H at 10 M
and 107 M inhibited IgG synthesis by 67% and 85%

respectively (5). The inclusion of anti-KR(32-52) in culture

was found to neutralize Suppression of SAC induced IgG
Synthesis in a dose dependent manner. In contrast, Similar
concentrations of normal RGG failed to neutralize the

observed Suppression.

0173 To assess the specificity of anti-KR(32-52) anti

body, PBMC were incubated with specific antibody or RGG
followed by co-culture with U50,488H or the u receptor

Selective agonist (DAGO) and IgG production measured by
ELISA. The results indicate that, whereas, anti-KR(32-52)

neutralized U50,488H-mediated inhibition of SAC-induced

IgG synthesis, anti-KR(32-52) was unable to neutralize

DAGO-mediated Suppression of IgG Synthesis.
0.174. These results indicate that in addition to binding

lymphocytes and macrophage, anti-KR(32-52) is capable of
neutralizing the ability of a KR selective agonist (U50,
488H), but not auR selective agonist (DAGO). Additionally
the antibody demonstrated significant inhibition of both
lymphocyte proliferation and differentiation to antibody
Synthesis. These results further demonstrate the Specificity

of acting as an KR Selective antagonist and neutralizing
U50,488H-mediated Suppression, PBMC cultures were pre
incubated with various concentrations of protein A purified

of anti-KR(33-52) for the human kappa receptor.
0.175 AS can be seen from the antibody binding data

anti-KR(32-52) prior the addition of SAC and U50,488H.
U50,488H Suppresses SAC-induced lymphocyte prolifera
tion in a dose dependent fashion (5). Maximal Suppression

presented above, the Site directed polyclonal antibodies
raised in rabbits using the C5a-agonist form of the molecular
adjuvant conjugated to the K receptor Sequence were capable
of binding to normal human cells and cell lines expressing
mRNA specific for the human K receptor. Flow cytometric

was obtained when U50,488H was used at a concentration

of 10 M. PBMC cultures were preincubated with various

concentrations of anti-KR(33-52) (1-50 ug/ml), followed by

the addition of U50,488H plus SAC, and proliferation

measured on day 3 of culture. Anti-KR(33-55) was found to

analysis of a neuronal cell line (NT2), normal blood-derived
CD14+monocytes, monocyte-like cell lines (U937 and
THP1), normal blood derived CD3+ T cells and a T cell line
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(Jurkat), and human B cell lines (SKW6.4 and CESS)
revealed that the cells were all bound by anti-KR(33-52) in
a specific manner. The anti-KR(33-52) did not bind to a cell

line determined not to express mRNA for the human K
receptor.

0176 Anti-KR(32-52) was found to specifically neutral
ize KR-selective agonist (U50,488H)-mediated inhibition of

lymphocyte activation. The antiserum was found to neutral
ize, in a dose dependent manner, U50,488H-mediated inhi

bition of: 1) SAC-induced lymphocyte proliferation; 2)
PHA-induced lymphocyte proliferation and; 3) SAC-in
duced IgG Synthesis. In contrast, DAGO-mediated Suppres
sion of SAC-induced IgG production was not affected by

anti-KR(32-52). These results suggest that this site directed

polyclonal antiserum Specifically interacts with the human
KR on PBMC. The results presented indicate that polyclonal

anti-KR(32-52) antibodies interact with the exposed N-ter

minal region of the KR. While this antiserum effectively
blocked U50,488H-mediated lymphocyte activation, it did
not activate macrophage or lymphocytes.
0177. While anti-Kopioid receptor antibodies are exem
plified above, conjugation of C5a agonist peptide to peptides
corresponding to p and Aspecific peptides has resulted in the
Successful generation of Specific antibodies to the p and A
epitopes.
EXAMPLE 4

Comparison of Immunogenicity of Epitope-C5a
Agonist Constructs with Epitope-KLH Conjugates
0.178 The following experiment was performed in order
to compare the potency of the molecular adjuvant of the
present invention with a widely used method for enhancing
the immune response to peptide epitopes. The objective was
a direct comparison of the response to a construct of MUC1
epitope-C5a agonist and the same epitope conjugated to

keyhole limpet hemocyanine (KLH) in mice. The results are
Summarized in Table 2.

0181 Five C57BL6 were immunized and boosted with
YKQGGFLGL-KLH (SEQ ID NO:6-KLH) and sera were
obtained as indicated in the Materials and Methods section.

Standard error of responder titer values was less then 25%
for IgM and less than 40% for IgG1.
0182. A similar experiment was performed in rabbits.
The immunogens used in rabbits were the K- and u-opioid

receptor epitopes, FPGWAEPDSNGSAGSEDAQL (SEQ
ID NO:9) and GDLSDPCGNRTNLGGRDSL (SEQ ID
No:11), respectively. The serum antibody titer and antibody

Subtypes produced in rabbits injected with the two compo
Sitions containing the different immunogens were compared.
0183) i. Peptide conjugates. In one instance the epitopes
were conjugated to KLH Via a lysine residue added Syn
thetically to the N-terminus of the epitope along with an
alanine residue which acted as a Spacer. In this experiment,
glutaldehyde was used to effect conjugation. In the another
case, the epitopes were linked to the N-terminal end of the

C5a agonist YSFKPMPLaR (SEQ ID NO:1) using the solid

phase peptide Synthetic methodologies described above in
example 1.
0.184 ii. Immunization protocol for rabbits. Rabbits were
immunized s.c. with 500 lug of either the epitope-KLH or the

epitope-YSFKPMPLaR (epitope-SEQ ID NO:1) constructs
in compete Freund's adjuvant (GIBCO, Grand Island, N.Y.).
Booster injections were administered on days 30 and 60 in
incomplete Freunds's adjuvant. Serum was collected Start
ing at day 60 post-immunization.
0185. iii. Antibody determination. The presence of rabbit
IgG Specific for the peptide epitopes was determined by

ELISA as previously described (8). Rabbits immunized with

the epitope-C5a agonist generated high titer IgG AbS Spe
cific for the opioid receptor peptide epitopes. The rabbits
immunized with the opioid receptor epitopes conjugated to
the carrier protein KLH also produced high titer antibodies
Specific epitopes to which they were injected. These results
demonstrate that the decapeptide C5a-agonist was as effec

TABLE 2

MUC1 Specific Ab Isotype Titers Produced with Different Immunogens.
Ab IsotVDes and Titers'
IgA IgG1
IgG2a IgG2b
IgG3 IgM
YKOGGFLGLYSFKPM
PLaRP

(SEQ ID NO: 2)

YKOGGFLGL-KLHe

O
O

O
100 (2/5)

1260 1780 (5/5) 0 (5/5) 6310 (5/5)
O

O

O

5010 (4/5)

(SEQ ID NO: 6-KLH)

0179 Sera were screened against MUC1 peptide and
mean titer values of responders are shown. Parentheses
indicate the number of responders. Ab titer is defined as the
Sera dilution within the linear range at which specific
reactivity is lost.

0180

Five C57BL6 mice were immunized and boosted

with YKQGGFLGLYSKFPMPLaR (SEQ ID NO:2) and
Sera were obtained as indicated in the Material and Methods

Section. Standard error of responder titer values was leSS
than 32% for all isotypes.

tive as the large molecular weight protein, KLH, conjugated
to the epitope at inducing Specific anti-peptide antibodies in
non-rodent species.
EXAMPLE 5

Evaluation of C5a Peptide to Function as a
Molecular Adjuvant and Epitope Delivery System
for a Defined CTL Epitope of Hepatitis B Virus
Surface Antigen
0186 Experiments were performed in which YSFKPM

PLaR (SEQID NO: 1) was used as a molecular adjuvant for
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inducing antigen-Specific CTL responses against a defined
CTL peptide epitope from the hepatitis B Surface antigen

(HBSAg). The HBSAg CTL epitope was covalently attached
to either the N-terminus of YSFKPMPLaR (SEQ ID NO: 1)
(C5a-active constructs) or to its C-terminus (C5a-inactive
constructs). Mice were immunized with these C5a-active

and C5a-inactive constructs in the absence of any added
adjuvant in order to evaluate the ability of YSFKPMPLaR

(SEQ ID NO: 1) to provide the necessary signals and/or

were given S.c. in the inguinal region at 21-day intervals.
Sera for Ab analysis were obtained by retro-orbital bleeds of
mice under CO2 narcosis.
0.192 Spleen cell cultures and in vitro stimulation. Three

weeks after Secondary (2) immunization and two weeks
after tertiary (3) immunization, two to three mice from each
experimental group were Sacrificed by cervical dislocation
and their spleens removed aseptically. Pooled Splenic Single
cell suspensions were prepared in RPMI-1640 medium

targeting required for the induction of an antigen-Specific
CTL response. Immunizations were also performed with
C5a-active constructs containing protease-Sensitive linker
sequences between the HBSAg CTL epitope and the C5a
agonist. The results of these experiments were analyzed in
terms of a possible mechanism by which YSFKPMPLaR

(Sigma, St. Louis, Mo.) containing 10% FBS (Hyclone, Salt
Lake City, Utah) and the following supplements: 10 mM

the importance of a protease-Sensitive Sequence between the
epitope and the C5a agonist.
0187 Materials and Methods:
0188 Peptide synthesis. Peptides were synthesized by
Standard Solid phase methodologies on an Applied BioSys

75x10 pooled spleen cells in 5 ml of RP10-SC were pipetted

(SEQID NO: 1) induces antigen-specific CTL responses and

tems (Foster City, Calif.) model 430Asynthesizer. Syntheses
were performed on a 0.25-mmol Scale and employed the
Fmoc (9-fluorenylmethyloxycarbonyl)method of repetitive
residue linkages. Peptide purification was accomplished
with analytical and preparative HPLC on columns packed
with Cs bonded Silica. All peptides were characterized by
amino acid compositional analysis and mass Spectrometry.
The details of these methods of Synthesis, purification, and

characterization have been described previously (Sanderson
et al., J. Med. Chem. 37, 3171, 1994).
0189 Pharmacologic assays. C5a-like agonistic activity
was assessed by the ability of the peptides to induce Smooth
muscle contraction of human umbilical artery and i release
from human PMNs according to previously published meth

ods (Sanderson et al., 1994, Supra; Sanderson et al., J. Med.
Chem. 38, 3669, 1995; Finch et al., J. Med. Chem. 40,877,
1997). Full concentration-response curves were generated
for individual peptides and natural C5a in each assay and the

ECso values (the concentration of peptide producing 50% of
the maximal response to each peptide) were calculated. pl.)
transforms -log ECso (M) were calculated for each con

HEPES buffer, 50 uM 2-ME, 2 mM L-glutamine, 50 lug/ml
gentamicin Sulfate, 100 U/ml penicillin, and 50 lug/ml Strep

tomycin (all Supplements from Sigma). This Supplemented

complete medium is designated RP10-SC. For culture,
into a 25 cm^ T-flask (Corning). Next, 5 ml of RP10-SC
containing 150 nM of synthetic, L' MHC class I-restricted

peptide, IPQSLDSWWTSL (SEQ ID NO:12) were added to
the flask. The flasks were incubated undisturbed in an
upright position at 37 C. in 5% CO. After 4 days of
incubation, the cells were recovered from the T-flasks,

washed, once by centrifugation in fresh RP10-SC, resus

pended in 5 ml RP10-SC, counted, and adjusted to 5x10°

viable cells/ml.

0193 Target cell lines. The specific cell target used for
measuring CTL activity was P815S, a transfectant cell line

of P815 (H-2) expressing the HBSAg (14). P815S was
disulfate (G418, Sigma). The parental H-2' mastocytoma

grown in RP10-SC medium containing 400 tug/ml geneticin

cell line, P815 (ATTC #TIB64) grown in RP10-SC medium,

was used as a non-specific target for CTL assays to measure
% non-Specific lysis. In all the experiments shown, this
value was less than 5% at effector-to-target ratios of 50:1.
0194 Target cell labeling. The target cells, either P815S
O P815, were washed 2 times in RP10-SC. For labeling,

5x10 target cells were mixed with 250 uCi Cr-sodium

chromate 400-1200 Ci (14.8-44.4 TBq)/g; NEN Dupont,
Boston, Mass.) in a 1.0 ml volume in a 50 ml conical tube

and incubated in a 37 C. water bath for 90 minutes. After

incubation, the labeled cells were washed 3 times by cen
trifugation using 15 ml volumes of fresh RP10-SC and
allowed to stand at room temperature for 30 minutes. The

centration-response curve and reported as the meantSE.
Peptide binding affinity to the C5aR was evaluated on intact

pelleted cells were resuspended in RP10-SC at 1x10 cells/

human PMNs by a competition assay using 'I-C5a accord

ml.

ing to previously described methods (Sanderson et al., 1995,
supra; Finch et al., 1997, Supra). Statistical analysis of the

cells at 5x10 cells/ml were serially diluted in triplicate in

using one-way analysis of variance (ANOVA).

wells of round-bottom 96 well plates (Corning, 25850) in a

values obtained from pharmacologic assays was performed

0190 Animals. Female BALB/c (H-2) mice 10 to 12

weeks old were purchased from the Jackson Laboratory (Bar
Harbor, Me...). On arrival, mice were housed in isolator
cages, provided autoclaved food and water ad libitum, and
quarantined for Seven days. On release from quarantine, the
mice were entered into the Study following written protocols

on file with the Animal Care and Use Committee and in

compliance with the Animal Welfare Regulations (9CFR).
0191 Immunization protocols. Groups of six to eight
BALB/c mice were given bilateral S.c. injections in the

inguinal area with (100 ul each side) of a PBS solution

containing 50-100 ug of the peptides. Booster injections

0.195 Cytotoxicity assay. The recovered splenic effector

total volume of 100 ul/well and using RP10-SC as the

diluent. Next, 100 ul volumes of Cr-labeled targets, P815S

or P815, at 1x10 cells/ml were added to the wells. Maxi
mum release (MR) wells contained 100 ul of target cells and
100 ul of 2% (v/v) Tween 20 while spontaneous release (SR)
wells contained labeled cells in medium alone. Effector-to

target ratios of 50:1, 25:1, 12.5:1, and 6.25:1 were routinely
employed. The plates were centrifuged at 400xg and incu
bated at 37° C. in 5% CO for 4 hrs. After incubation, the
Supernatant fractions in the Wells were collected using a

Skatron Supernatant Collection System (Skatron Instru
ments, Sterlin, Va.). The amount of Cr radioactivity in the
Supernatant fractions was measured using a Wallac 1470

Wizard gamma counter (Turku, Finland). Percent specific
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lysis was calculated as (experimental release-SR/(MR
SR)x100. The SR was always less than 10% of the MR. All

assays were performed in triplicate.
0196) Results:
0197) Peptide design. Peptide immunogens were
designed to evaluate the requirement for C5a agonist activity
in the induction of Antigen-Specific CTL responses. C5a
active constructs were generated by the covalent attachment
of the HBSAg CTL epitope to the N-terminus of the C5a

agonist: IPQSLDSWWTSLYSFKPMPLaR (SEQ ID NO:
13) IPQSLDSWWTSLRRYSFKPMPLaR (SEQ ID NO:
14), and IPQSLDSWWTSLRVRRYSFKPMPLaR (SEQ ID
NO: 15). This positioning of the CTL epitope relative to the

C5a agonist leaves the biologically important conforma
tional features expressed in the C-terminal region of

YSFKPMPLaR (SEQID NO: 1) free to interact with C5aRs

expressed on the cells involved in antigen uptake and
processing. The latter two peptides were designed to evalu
ate if predicted protease-Sensitive linker Sequences placed
between the HBSAg CTL epitope and the C5a agonist might
facilitate intracellular release of the epitope into antigen
presenting pathways and thereby enhance the response. The

linkers consisted of a dibasic double-Arg (RR) Sequence,

which is Susceptible to cleavage by proteases of the Subtili
Sin family and trypsin-like proteases. The other was a
Sequence Sensitive to the ubiquitous intracellular Subtilisin

like protease furin, RVRR (SEQ ID NO: 19). This latter
Sequence is found at the junction of the A and B fragments
of diphtheria toxin (DT) and it is believed that furin plays a
prominent role in the intracellular proteolytic activation of
DT and several other bacterial toxins as well as in the

processing of proproteins and prohormones that contain the

consensus sequence RX(K/R)R. C5a-inactive constructs

were generated by blocking the functionally important car

boxyl group on the C-terminal Arg of YSFKPMPLaR (SEQ
ID NO:1) with either the HBSAg CTL epitope, YSFKPM
PLaRRRIPQSLDSWWTSL (SEQID NO: 16) or with a Gly
residue, IPQSLDSWWTSLRRYSFKPMPLaRG (SEQ ID
NO: 17).
0198 Pharmacologic activities. All peptides were evalu
ated for C5a agonist activities in assays that measured
peptide-mediated contraction of Smooth muscle in human

umbilical artery (Table 3), the release of MPO from human
PMNs (Table 4), and binding to C5aRs expressed on the
surface of human PMNS (Table 5). Constructs in which the
HBSAg CTL epitope was attached to the N-terminus of the

C5a agonist, IPQSLDSWWTSLYSFKPMPLaR (SEQ ID
NO: 13), IPOSLDSWWTSLRRYSFKPMPLaR (SEQ ID
NO: 14), and IPQSLDSWWTSLRVRRYSFKPMPLaR
(SEQ ID NO: 15) behaved as full agonists relative to natural
C5a with potencies and C5aR binding affinities comparable

to or greater than YSFKPMPLaR (SEQ ID NO: 1). In

contrast, the construct in which the functionally important
C-terminal carboxyl group of the C5a agonist moiety was
blocked with the HBSAg CTL epitope YSFKPMPLaR

RRIPQSLDSWWTSL (SEQ ID NO: 16) was significantly
less potent in umbilical artery contraction (Table 3), inactive
in MPO release from PMNs (Table 2), and bound poorly to
the C5aR (Table 5) relative to both natural C5a and YSFKP
MPLaR (SEQ ID NO: 1). Similarly, the construct in which
a Gly residue blocked the C-terminal carboxyl group of the
agonist moiety IPOSLDSWWTSLRRYSFKPMPLaRG

(SEQ ID NO: 17) was significantly less potent than its
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C5a-active counterparts in umbilical artery contraction

(Table 3) and bound with significantly less affinity to the
C5aR (Table 5). This construct was unable to induce a full
response relative to natural C5a in MPO release from PMNs

(Table 4). CTL responses are induced in mice when the L'

MHC class I restricted peptide, Sso, of HBSAg is
covalently attached to the N-terminus of the C5a agonist via
an Arg-Arg linkage. Initial experiments were designed to

evaluate CTL induction by the free L' MHC class I-re

stricted peptide Ss, IPQSLDSWWTSL (SEQ ID NO:
12), the same peptide with two Arg residues added to the
C-terminus, IPQSLDSWWTSLRR (SEQ ID NO: 18), the
free C5a agonist, YSFKPMPLaR (SEQ ID NO: 1) and

admixtures of the above peptides. Of particular interest was
the evaluation of C5a-active constructs in which the HBSAg
CTL epitope was covalently attached either directly to the
N-terminus of the C5a agonist IPOSLDSWWTSLYSFKP

MPLaR (SEQ ID NO: 13) or through the double-Arg,
protease-sensitive linker IPOSLDSWWTSLRRYSFKPM

PLaR (SEQ ID NO: 14). The administered amounts of the
latter two constructs were adjusted to reflect amounts equal
(by weight) to that of the free HBSAg CTL epitope based on
relative molecular mass. Mice in each group received two
injections, Spaced 21 days apart, of the indicated construct.
Mice in each group were tested for Splenic CTL activity at
day 42 as described in Materials and Methods. As shown in
Table 6, only the group injected with the double-Arg-linked

construct IPQSLDSWWTSLRRYSFKPMPLaR (SEQ ID
NO: 14) exhibited a significant CTL response against the
P815S transfected target cells.
0199 C5a agonist activity is necessary for the induction
of antigen-specific CTL responses. To evaluate the necessity
of C5a agonist activity in the induction of antigen-specific
CTL responses, mice were immunized with C5a-active and
C5a-inactive HBSAg CTL epitope-containing constructs.
C5a-active constructs were generated by the covalent attach
ment, via the protease-Sensitive, double-Arg linker
sequence, of the HBSAG CTL epitope to the N-terminus of
the C5a agonist IPOSLDSWWTSLRRYSFKPMPLaR
(SEQ ID NO: 14). C5a-inactive constructs were generated
by blocking the functionally important carboxyl group on
the C-terminal Arg of the C5a agonist with either the HBSAg

YSFKPMPLaRRRIPQSLDSWWTSL (SEQ ID NO:16) or a
Gly residue IPQSLDSWWTSLRRYSFKPMPLaRG (SEQ
ID NO: 17). The double-Arg-containing HBSAg CTL
epitope IPQSLDSWWTSLRR (SEQ ID NO: 18) was used
as a control. AS shown in FIG. 1, only mice that were
immunized with the C5a-active construct IPOSLDSW

WTSLRRYSFKPMPLaR (SEQ ID NO:14) generated an

antigen-specific CTL response. The phenotype of the effec
tor cells responsible for the in vitro cytolytic activity in these
experiments was determined to be CD8+ as judged by the

ability of a rat anti-mouse lyt 2.2 MAb (2.43, ATCC TIB
210) to almost completely inhibit (greater than 90% inhibi
tion) the cytolytic process. In contrast, a rat anti-mouse
L3T4 monoclonal antibody (GK1.5, ATCC TIB-207) known
to block CD4 T cell activity had no effect on the in vitro

cytolysis induced by the active constructs (data not shown).
0200 CTL responses are induced only by C5a-active

constructs containing a protease-Sensitive linker Sequence
between epitope and C5a agonist. To evaluate the require
ment for a protease-Sensitive linkage between the HBSAg
CTL epitope and the C5a agonist for CTL induction, mice
were immunized with C5a-active constructs in which the
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HBSAg CTL epitope was covalently attached directly to the
N-terminus of the C5a agonist IPOSLDSWWTSLYSFKP

TABLE 3-continued

MPLaR (SEQ ID NO: 13) or separated by protease-sensitive

linker sequences IPOSLDSWWTSLRRYSFKPMPLaR

Immunogen Activity in Smooth Muscle Contraction
of Human Umbilical Artery

(SEQ ID NO: 14) and IPQSLDSWWTSLRVRRYSFKPM
PLaR (SEQ ID NO: 15). As noted previously, the double
Arg (RR) Sequence is sensitive to cleavage by proteases of
the Subtilisin family and other trypsin-like proteases. The

RVRR (SEQ ID NO: 19) sequence is a motif recognized by
the intracellular protease furin. The results shown in FIG. 2
indicate that of the three C5a-active constructs, only those
containing the protease-Sensitive linker Sequence between
the HBSAg CTL epitope and the C5a agonist were capable
of inducing an antigen-Specific CTL response in mice.
Although the RVRR-containing construct was able to elicit
a specific CTL response that was significantly above back
ground levels, the response did not exhibit an enhanced
magnitude of lysis or more rapid kinetics of induction when

compared with that of the RR-containing construct (data not
shown). This finding Suggests that intracellular furin likely

plays a leSS Significant role, or perhaps no role, in the
processing of the epitope-C5a agonist construct than other
intracellular proteases with Specificity for basic or dibasic

ECso

Peptide (SEQ ID NO:)
YSFKPMPLaRRRIPQSLDSWWTSL (16)
IPOSLDSWWTSLRRYSFKPMPLaRG (17)

opioid receptor epitope-C5a agonist constructs (see previous
examples) induced antibody responses to the MUC1 and

4.41

O.O6
5.17 O.13*
6.67 + 0.22

IPOSLDSWWTSLRVRRYSFKPMPLaR

(um)

in

39.4

3

6.78
O.18

3
3

(15)
pD = -log Ecs (M) expressed as mean it SE

ECso concentration of peptide resulting in 50% maximum contraction
in represents the number of measurements performed
*significant change from YSFKPMPLaR, P < 0.05

0202)
TABLE 4

residues.

0201 Antibodies to the HBSAg CTL epitope or the C5a
agonist are not produced by immunization with the HBSAg
CTL epitope-C5a agonist constructs. Previous Studies
showed that immunization of mice in the presence of
additional adjuvant with MUC1 epitope-C5a agonist and

pD, E SE

Immunogen Activity in MPO Release for Human PMNS
ECso

Peptide (SEQ ID NO:)

pD, E SE

(um)

in

C5a

8.50 it 0.39

O.OO3

3

YSFKPMPLaR (1)
IPOSLDSWWTSLYSFKPMPLaR (13)

5.88 O.17
5.80 - 0.04

132
1.58

3
3

opioid receptor epitopes and the full-length, intact proteins.

IPOSLDSWWTSLRRYSFKPMPLaR (14)

6.27 + 0.29

0.54

3

YSFKPMPLaRRRIPQSLDSWWTSL (16)

>3

>1 mM

3

Thus, it was of interest to determine whether Sera from mice

5.59 + 0.28

2.56

3

(17)
5.61 - 0.19

2.15

3

immunized with the control peptides and epitope-C5a ago
nist constructs contained antibody directed against any of
the peptides. Mice were bled at various times following
injection and the Sera from all groups were tested by ELISA

IPOSLDSWWTSLRRYSFKPMPLaRG
IPOSLDSWWTSLRVRRYSFKPMPLaR

(15)
pD = -log Ecso (M) expressed as mean it SE
ECso concentration of peptide resulting in 50% maximum release of
myeloperoxidase
in represents the number of measurements performed

for reactivity with YSFKPMPLaR (SEQ ID NO: 1),
IPOSLDSWWTSL (SEQ ID NO: 12), IPOSLDSW
WTSLRR (SEQ ID NO: 18), and IPQSLDSWWTSLRRYS
FKPMPLaR (SEQ ID NO: 14). These analyses failed to

9% of the maximum C5a-induced enzyme release (P > 0.05) compared to
YSFKPMPLaR (SEQ ID NO: 1).

(optical densities equal to normal mouse Serum at a 1:50
dilution of the Serum). However, Sera taken from mice

0203)

show binding to either the C5a agonist or the CTL epitopes

This peptide displayed partial agonist activity up to 1 mM achieving 49 it

following three injections of IPOSLDSWWTSLRRYSFKP

TABLE 5

MPLaR (SEQ ID NO: 14) yielded an ELISA titer of 1:1600
against the immunizing peptide, but did not bind the free

peptides IPOSLDSWWTSLRR (SEQ ID NO: 18) or
YSFKPMPLaR (SEQ ID NO: 1). These results suggest that
the C5a-active, RR-containing construct contributes to the
formation of a neo-B cell epitope that is presented via the
class II pathway.
TABLE 3

Immunogen Activity in Smooth Muscle Contraction
of Human Umbilical Artery

Peptide (SEQ ID NO:)

pD, E SE

ECso

(um)

C5a

8.77

O.14

O.OO2

YSFKPMPLaR (1)
IPOSLDSWWTSLYSFKPMPLaR (13)
IPOSLDSWWTSLRRYSFKPMPLaR (14)

6.99
6.68
6.79

0.22
0.17
0.31

O.O10
O.21
O161

Immunogen Binding Affinity for CSaRS On Human PMNS

Peptide (SEQ ID NO:)

pD, E SE

ECso

(um)

in

O.OOO4

3

CSa

9.43 - 0.11

YSFKPMPLaR (1)
IPOSLDSWWTSLYSFKPMPLaR (13)
IPOSLDSWWTSLRRYSFKPMPLaR (14)
YSFKPMPLaRRRIPOSLDSWWTSL (16)
IPOSLDSWWTSLRRYSFKPMPLaRG

5.63 - 0.10
2.34
5.43 - 0.16
3.69
6.38 O.17*
O.416
3.33 O.O9* 465
4.77 O.33*
17.0

3
3
3
3

6.28. O.14

3

3

(17)
IPOSLDSWWTSLRVRRYSFKPMPLaR

0.529

(15)
pD = -log Ecs (M) expressed as mean it SE
ECso concentration of peptide resulting in 50% inhibition of 'I-C5a
binding
in represents the number of measurements performed
*Significant change from YSFKPMPLaR, P < 0.05.

Apr. 28, 2005

US 2005/0O89524 A1

noted that the failure of the free HBSAg peptide epitope to
elicit a CTL response could be attributable to degradation
after injection of internalization. Thus, it might be consid
ered that the attachment of the epitope peptide to the
N-terminus of the RR-containing C5a agonist peptide might,
in part, reduce the Sensitivity of the epitope to degradative
effects. Such stabilization of the CTL epitope could, in part,

0204)
TABLE 6

Percent Specific Lysis of "Cr-Labeled P815S
Target Cells from Mice Immunized with Various
HBSAg CTL Epitope/C5a Agonist Peptides.

injected)

IPOSLDSWWTSL (12) (25)
IPOSLDSWWTSLYSFKPMPLaR (13)

contribute to the effectiveness of the co-linear RR-contain

% Specific Lysis
Effector: Target Ratio

Peptide (SEQ ID NO:) (ug
SO:1

25:1

12.5:1

6.25:1

7
6

5
4

3
2

3
1.

(47)
IPOSLDSWWTSLRR (18) (25)

2

2

1.

O

32

23

14

9

YSFKPMPLaR(1) (25)

1.

2

O

1.

IPOSLDSWWTSL (12) (25) +

1.

2

1.

1.

2

O

O

O

1.

1.

1.

O

IPOSLDSWWTSLRRYSFKPMPLaR

(14) (42)
YSFKPMPLaR(1) (25)
IPOSLDSWWTSLRR (18) (25) +

YSFKPMPLaR(1) (25)
Normal Spleen Cells

The CTL response was measured against the H-2' cell line (P815S) a

transfectant that expresses the HBs.Ag. Normal P815 cells were used as a

measure of non-specific lysis. % lysis against 'Cr-labeled P815 targets

ranged between 0-5% at a 50:1 effector-to-target ratio (data not shown).
BALB/c mice were injected s.c. with the indicated peptides in PBS. Mice
were boosted on day 21 and spleen cell suspensions from each group were
prepared on day 42 and restimulated as in vitro cultures for 4 days in the
presence of HBs.Ag Se peptide, IPQSLDSWWTSL.

0205 Discussion:
0206 AS can be seen from the results presented above,
the conformationally biased C5a agonist YSFKPMPLaR
(SEQ ID NO: 1) serves as an effective molecular adjuvant,

in this case by inducing antigen-specific CTL responses
against a well-defined T cell epitope derived from the
HBSAg. The CTL responses were CD8 and were observed
only in mice that were immunized with C5a-active con
structs in which the HBSAg CTL epitope was covalently

attached to the N-terminus of YSFKPMPLaR (SEQ ID NO:
1) (i.e., IPOSLDSWWTSLRRYSFKPMPLaR(SEQID NO:
14) and IPQSLDSWWTSLRVRRYSFKPMPLaR (SEQ ID
NO: 15)). This arrangement leaves the biologically impor
tant conformational features in the C-terminal region of
expressed on the cells involved in the immune responses and
underScores the necessity of C5a agonist activity in the
generation of the observed CTL response. However, the
presence of C5a agonist activity in the epitope-C5a agonist
constructs alone was not Sufficient in generating HBSAg
specific CTL responses. This was indicated by the lack of a
CTL response in mice immunized with IPQSLDSW

YSFKPMPLaR (SEQID NO: 1) free to interact with C5aRs

WTSLYSFKPMPLaR (SEQ ID NO: 13), despite the fact

that this construct behaved as a full agonist of C5a. It is
noteworthy that this C5a-active construct lacked a protease
Sensitive linker Sequence Separating the epitope moiety from
the C5a agonist moiety that was present in the two C5a
active constructs that generated a CTL response-either the

double-Arg (RR) or the furin protease-specific sequence
RVRR (SEQ ID NO: 19). That CTL responses were

observed only in mice immunized with C5a-active con
Structs that contained these protease-Sensitive Sequences
between the epitope and C5a agonist moieties Supports the
concept that during the internalization of the C5aR/ligand
complex an intracellular cleavage event may separate the
epitope from the agonist to facilitate the entry of the epitope
into intracellular antigen presentation pathways. It should be

ing constructs. However, it is unlikely that Such a phenom
enon represents the Sole mechanism involved Since blocking
the C-terminus of the C5a agonist moiety in these constructs
abrogates their ability to elicit a CTL response, thereby
indicating an essential role for C5a agonist activity in the
observed responses.
0207. It is also noteworthy that the C5a-active constructs

IPOSLDSWWTSLRRYSFKPMPLaR (SEQ ID NO: 14)
and IPOSLDSWWTSLRVRRYSFKPMPLaR (SEQ ID NO:
15) induced robust CTL activity after a 2 boost in the

absence of any added adjuvant. This observation Suggests
that the C5a agonist moiety is capable of eliciting the T cell
help necessary to induce the observed CD8 CTL response.
It is likely that this T cell involvement emanates from the
ability of the C5a agonist moiety to induce the release of
immunopotentiating cytokines from C5aR-bearing APCs
with which the epitope-C5a agonist constructs interact. This
Supposition is Supported by the fact that C5a has been shown

to induce the synthesis and release of IL-1 B, IL-20), IL-8,

and IL-12 from human monocytee and IL-1B, IL-6, IL-8,
IL-12, TNF-C, and IFN-Y from human dendritic cells. The
C5a agonist moiety, therefore, appears capable of both
targeting the attached epitope to C5aR-bearing APCs and
eliciting the appropriate immunopotentiating activity. Thus,

the YSFKPMPLaR(SEQID NO: 1) moiety of the constructs

used in these immunizations can be viewed as a molecular

entity that embodies adjuvant properties characteristic of
both a “targeting vehicle' and an “immunomodulator”.

Finally, mice immunized with YSFKPMPLaR (SEQID NO:
1) containing constructs displayed no outward physical signs
that would be characteristic of a C5a-mediated anaphylactic

response. This in vivo use of YSFKPMPLaR (SEQ ID NO:
1) and lack of associated toxicity in consistent with the

response-Selective activities that have been observed in

vitro.

0208. The results described herein are consistent with a
mechanism described in the previous examples. The

YSFKPMPLaR (SEQ ID NO: 1) moiety of the HBSAg

constructs interacts with C5aRS expressed on the Surface of
APCs to induce the synthesis and release of cytokines that
activate T cells. Following C5aR activation and cytokine
release, the C5aR/ligand complex internalizes allowing
intracellular proteases to Separate the HBSAg epitope from

the C5a agonist by cleaving at the double-Arg (RR) or
furin-specific sequence (RVRR (SEQ ID NO: 19)) that

Separate these two moieties. The HBSAg epitope then asso
ciates with MHC class I determinants that are subsequently
expressed on the APC surface. While this mechanism of
CTL induction by the C5a agonist-containing constructs
remains is but one of Several possibilities, it may involve a
novel pathway of exogenous MHC class I antigen presen
tation. Since it had been generally assumed that class
I-mediated antigen presentation involved the generation of
peptides from endogenously Synthesized proteins, the find
ing that extracellular Soluble proteins could be taken up by
professional phagocytes (macrophages and dendritic cells),
processed in the cytoplasm or perhaps endoSomes to yield
antigenic peptides, which are presented in association with
MHC class I molecules, is of considerable Significance.
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Presentation of extracellular antigens would be expected to
be most efficient when they are particulate in nature and,
consequently, are more Susceptible to phagocytosis by mac
rophages and dendritic cells. In the case of the C5a agonist
constructs, it is possible that targeting the C5aR on Such cells
might accomplish a similar enhancement of presentation in
the MHC class I pathway. Such a proposal Seems especially
tenable in light of the recent findings that Subunits of Several
bacterial toxins, especially anthrax toxin, when coupled to
protein and peptide antigens, are capable of effecting inter
nalization of the antigens and delivering them into the class
I presentation pathway with resultant antigen-specific CTL
production. Finally, it is noteworthy that a proteoSome
independent, furin-dependent Viral antigen processing path
way where cleavage occurs in the Golgi or post-Golgi
Secretory pathway has been recently described. Again, this
finding Suggests that interSection of internalized antigens/
peptides with elements of the anterograde Secretory pathway

(endoSomal or trans-Golgi region), as may occur with C5aR/

ligand complexes, could result in processing events and
asSociation with unoccupied class I molecules that are in
transit through this pathway.
0209 Although an exogenous pathway of intracellular
processing of the epitope-RR-C5a agonist constructs
appears to be a plausible mechanism, it is also possible that
the HBSAg epitope peptide is introduced onto MHC class I
determinants expressed on the surface of the APC. Thus, the
co-linear peptides containing the RR-C5a agonist moiety
could bind to the surface of APCs and, after proteolytic
cleavage of the Scissile linkage, the HBSAg CTL epitope
could displace lower affinity endogenous peptide in cell
Surface class I molecules. At present, the relative contribu
tion of extracellular and intracellular processing events in
CTL induction mediated by the C5a agonist moiety has not
been assessed. Further in vitro experiments are being
designed to address this issue.

0210. In contrast to formulating peptide and/or protein
antigens as particulates or as toxin Subunit-conjugates or
other derivatives, the C5a agonist peptide, rather than Serv
ing as an inert carrier, might provide the added benefit of
delivering immunopotentiating Signals. Accordingly, Such
constructs, containing either covalently linked peptides or
proteins, might be of particular benefit in those situations
where the target proteins or peptides are nominally immu
nogenic irrespective of the delivery vehicle or construct
employed. In the case of peptides, a further advantage of this
technology is that the C5a agonist constructs are relatively
Simple to produce and do not require recombinant technolo
gies and associated protein purification methodologies or
Specialized formulation procedures.
0211 The antigen-specific responses to well-defined T
cell and B cell epitopes observed in our Studies Support the
potential use of YSFKPMPLaR (SEQ ID NO: 1) and other
response-Selective C5a agonists as molecular adjuvants for
inducing a defined spectrum of humoral and/or cellular
responses against peptide, protein, and, possibly, non-pro
tein antigens. Such as possibility would provide a broad
based adjuvant/delivery technology that would be applicable
to a number of infectious and oncologic diseases in either
prophylactic or therapeutic Settings.
EXAMPLE 6

Evaluation of Nicotine Vaccine Compositions for
Recruitment and Activation of Antigen Presenting

Cells (APCs) and Stimulation of an Immune

Response in Mice
0212 i. Construction of the Nicotine Vaccine Composi
tions. The nicotine Vaccine composition was Synthesized by
first generating the nicotine hapten 5 by the route shown in
Scheme 1.

SCHEME 1.
HOOC

21

s

HO

N

O

c, d

21

s

N

--

s

CH

s

CH

2

3

fg
O

--21

HN

N

s

Key: (a) CH3NH2, 3A molecular sieves; (b) succinic anhydride, A, (c) MeOH, H2SO4 (cat.) (d) LAH;

(e) TosCI, EtN: (f) NaNa, DMF, A; (g) LAH; (h) succinic anhydride.

N
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0213. Once generated, 5 was then converted into an
activated ester and coupled to the N-terminus of YSFKP

MPLaR (the molecular adjuvant, SEQ ID NO:1) and
YKQGGFLGLYSFKPMPLaR (a B cell epitope-molecular
adjuvant construct, SEQ ID NO:2) during the solid-phase

Synthesis of these peptides according to Scheme 2.

SCHEME 2
O
O-HBTU
NH
O

--

N
CH

'.

HN-YKQGGFLGLYSFKPMPLaR

n
N

HN-YSFKPMPLaR

2
O
NH-YSFKPMPLaR
NH
O

-YKOGGFLGLYSFKP

''
CH

N
2

N

NH-YSFKPMPLaR

NH

-YKOGGFLGLYSFKPMPLaR

Acidolysis

O

Nicotine Vaccine Constructs

0214. The two C5a-active nicotine vaccine constructs
(Nic-YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID NO:2)
and Nic-YSFKPMPLaR (Nic-SEQ ID NO:1)) were purified
and characterized by Standard methods as detailed above.
0215 ii. Animal Models. Five groups of male Wistar rats

using a conjugate of 5 (Nic) to various proteins and their
unmodified controls as the coating antigens.
0216) iii. Results
TABLE 7

(ca 275 g) were immunized every other week with: 1) PBS
2) Nic-YSFKPMPLaR(Nic-SEQID NO:1), 3) Nic-YSFKP
MPLaR (Nic-SEQ ID NO: 1) in Freund's adjuvant, 4) Nic
YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID NO:2), and 5)
Nic-YKQGGFLGLYSFKMPMPLaR (Nic-SEQ ID NO:2)
in Freund's adjuvant. Primary immunizations were accom
plished by Subcutaneous (s.c.) and intrapertioneal (i.p.)

Reactivity of antiserum from rats immunized with
nicotine-modified peptide immunogens on bovine serum
albumin (BSA) unmodified or modified with nicotine.

Antigen Coating the Plate

injection of 100 lug of the peptides as indicated above in the
presence or absences of complete Freund's adjuvant. Boost
ing was performed in identical fashion at two-week internals
with 100 lug of the peptides in the presence of absence of
Freund's adjuvant. Sera were obtained by retro-orbital sinus
puncture one week after the third injection. The presence of

CSa-Nic
C5a-Nic

anti-nicotine antibodies in immune Serum was demonstrated

Freunds

by Standard enzyme-linked immunosorbant assay (ELISA)

Immunogen
PBS

Raw Data

Modified Minus
Unmodified

ng/ml

ng/ml

BSA

BSA-Nic

BSA

BSA-Nic

O

O

O

O

466
1,304

4,320
8,986

O
O

3,854
7,682
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TABLE 7-continued

mixed in a quasi-random fashion within two 8-Session
cycles that included 4 Saline and 4 nicotine Sessions. On

Reactivity of antiserum from rats immunized with
nicotine-modified peptide immunogens on bovine serum

Saline Sessions, rats were injected S.c. with Saline (0.9%
NaCl) and placed in the experimental apparatus for 20

albumin (BSA) unmodified or modified with nicotine.

for 15 seconds, but no food was delivered. Saline sessions,

Antigen Coating the Plate

Immunogen

minutes. Following variable delays, 8 lights were presented

Raw Data

Modified Minus
Unmodified

ng/ml

ng/ml

BSA

BSA-Nic

BSA

BSA-Nic

B-cell-C5a-Nic

1298

35,241

O

33,943

B-Cell-C5a-Nic

O

15,371

O

15,371

Freund's

therefore, provided a baseline with which to determine if the
vaccine affected behavior independent of the presence of
nicotine. On nicotine Sessions, rats were injected S.c. with

nicotine (0.4 mg/kg base) and placed in the apparatus for 20
minutes. The light cues were followed by 4-Second access to
the Sucrose. Thus, nicotine plus light Signaled food access,

light alone (i.e., Saline Sessions) signaled no food.
0220. In early Sessions, food Seeking, as measured by
breaks in an infrared beam where Sucrose is accessed

Nic-YSFKPMPLaR (SEQ ID NO: 1)

Nic-YKQHGGFLGLYSFKPMPLaR (SEQ ID NO: 2)

0217. As shown in Table 7, only those rats immunized
with C5-a-active constructs (Nic-YSFKPMPLaR (Nic-SEQ
ID NO:1), and Nic-YKQGGFLGLYSFKMPMPLaR (Nic
SEQ ID NO:2)) generated significant concentrations (ng/m;)
of anti-Nic antibodies. Although good results were obtained

in the presence of adjuvant (Freund's), it is noteworthy that

concentrations of anti-Nic antibodies were generated in the
absence of Freund's adjuvant.
0218. As shown in FIG. 7, when these antisera were
tested on other nicotine-modified peptides, Nic-YSFKPM

PLaR (C5a-Nic, (SEQ ID NO:1)) and Nic-YKOGGFLGL
(B-Cell-Nic, (SEQ ID NO:6)), the antibody reactivity was
still highest in the serum from rats immunized with Nic

YKQGGFLGLYSFKPMPLaR (SEQ ID NO:2) in the pres
ence of Freund's adjuvant (172,647 ng/ml). However, Nic
YSFKPMPLaR (C5a-Nic, (SEQ ID NO:1)) in the presence
and absence of Freund's adjuvant also induced responses to

nicotine as determined by reactivity to C5a-Nic (Nic-YS
FKPMPLaR, (SEQ ID NO:1)) and the B-Cell-Nic (Nic
YKQGGFLGL, (SEQ ID NO:6)).
EXAMPLE 7

Attenuation of Nicotine Induced Behavioral Effects
in Rats

0219. In order to determine the ability of the nicotine
vaccine compositions of the invention to attenuate behav
ioral effects of nicotine addiction, 16 male Sprague-Dawley
rats weighing approximately 300 grams were divided into

two groups (with eight rats in each group) and each group
was administered a different treatment regiment. All nicotine
compositions were prepared as described in Example 6. In
one treatment group, eight rats were vaccinated with 1000

(hereinafter "dipper entries”), should be high. Dipper
entries, however, should decrease in Saline Sessions because

no Sucrose is being delivered. Indeed, food Seeking System
atically decreased acroSS Saline Sessions in a pattern Similar

for vaccinated and non-vaccinated rats (FIG. 8, Panel A).

This outcome indicates that the vaccine does not differen

tially affect behavior in this preparation when nicotine is not
present. In contrast, there is a clear difference in food
Seeking behavior in the nicotine Sessions. Dipper entries
remained high in non-vaccinated rats likely reflecting a
"Summation' of food-seeking behavior maintained by occa
Sional Sucrose delivery and the psychomotor Stimulant
effects of nicotine. Notably, dipper entries in vaccinated rats
decreased below the levels of non-vaccinated rats. The

results depicted in FIG. 8 demonstrate the ability of the
nicotine vaccine composition to attenuate the centrally
mediated psychomotor effects of nicotine in vaccinated rats
during the first cycle of training. This interpretation is
Supported by an omnibus 3-way mixed factorial analysis of

variance with Group (Vaccinated VS. non-vaccinated) as a
between-Subjects factor, and Session (1 to 4) and Session
Type (nicotine or Saline) as within-Subject factors. The main
effects of Group, Session, and Session Type were all Statis
tically Significant, pS less than or equal to 0.002. Further, the

Group X Session Type interaction, F(1,14)=6.31, p=0.025
and the Session X Session Type interaction, F(3,42)=5.024,

p=0.005, were significant. The Session X Group and the
Session X Group X Session Type interactions were not
Significant, p greater than or equal to 0.34. Subsequent
Statistical contrasts to investigate the Source of the Group X
Session Type interaction were limited to comparing vacci
nated and non-vaccinated rats within each Session type.
Vaccinated rats displayed Significantly leSS dipper entries
than non-vaccinated rats on nicotine Sessions 2 and 3, ps
less than 0.05, indicating that the vaccine was effective at
attenuating the effects of nicotine in this animal model.
0221 FIG. 8, Panel B shows the index of learning

mg of Nic-YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID
No.2) (500 mg s.c. and 500 mg i.p.) dissolved in sterile

elevation Score for the first light (before Sucrose is given). A

saline and boosted in identical fashion every week for 2
weeks. The Second group of eight was sham immunized and
boosted with sterile Saline. Following the last boost, the rats
100% free-feeding weight was slowly decreased by 15%

in a comparable time just before the light occurred (light
dipper entries minus pre-light dipper entries). AS can be

across a week (i.e., target weight). This target weight insured
that the rats would seek 32% (w/v) liquid Sucrose in the

experimental apparatus. On dayS 1 to 3, rats were taught to
access 4-Second deliveries of liquid Sucrose in the apparatus.
For the following 16 days, rats in the vaccinated and

non-vaccinated groups were shifted to a or nicotine) inter

positive elevation Score indicates learning in that more
dipper-entries are occurring during the 15-Second light than

Seen, by the end of the first cycle rats are just learning that
Sucrose is being delivered during the light only on nicotine
Sessions. This indeX does not differ between vaccinated and

non-vaccinated rats. Analyses confirm these observations.
There was a main effect of Session and Session Type, pleSS
than or equal to 0.012. No other factors were significant, p
greater than or equal to 0.076. Notably, the vaccine did not
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produce a general insensitivity to Sucrose reward. Evidence
for this comes from the Similar acquisition rate of anticipa
tory dipper entries in vaccinated and non-vaccinated rats.
0222 AS training continued and rats learned to discrimi

exemplified above, it is not intended that the invention be
limited to such embodiments. Various modifications may be
made to the invention without departing from the Scope and
Spirit thereof as Set forth in the following claims.

nate nicotine sessions from saline sessions (FIG. 8, Panel B),
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1. A compound comprising a molecular adjuvant linked to
a nicotine hapten, the molecular adjuvant comprising a
targeting ligand having binding affinity for a characteristic
determinant of an antigen presenting cell, the targeting
ligand being functionally linked to the nicotine hapten,
whereby binding of the molecular adjuvant to the antigen
presenting cell determinant activates the antigen presenting
cell, effecting delivery of the nicotine hapten to an antigen
presenting pathway of the antigen presenting cell.
2. The compound of claim 1 wherein the targeting ligand
of the molecular adjuvant binds Specifically to a determinant
comprising an immunomodulatory receptor of the antigen
presenting cell.
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3. The compound of claim 1 wherein the targeting ligand
of the molecular adjuvant binds Specifically to a receptor
Selected from the group consisting of C5a receptor, IFN

gamma receptor, CD21 (C3d) receptor, CD64 (FcgRI)
receptor, and CD23 (FceRII) receptor.
4. The compound of claim 1 wherein the targeting ligand
of the molecular adjuvant binds Specifically to a C5a recep
tor and is Selected from the group consisting of C5a and a
peptide agonist analog of C5a comprising the C-terminal ten

10. The compound of claim 4 wherein the nicotine hapten
is linked to the N-terminus of the peptide comprising the
molecular adjuvant.
11. The compound of claim 10 wherein the nicotine
hapten is linked to the N-terminus of the peptide comprising
the molecular adjuvant by an amide bond.
12. The compound of claim 1 wherein the compound has
a structure corresponding to:

residues of C5a.

5. The compound of claim 1 wherein the targeting ligand
of the molecular adjuvant is a peptide comprising the
sequence YSFKKPMPLaR, which is SEQ ID NO:1.
6. The compound of claim 1 wherein the targeting ligand
of the molecular adjuvant is a peptide comprising the
sequence YKQGGFLGLYSFKPMPLaR, which is SEQ ID

NH-YSFKPMPLAR.
NH

NO:2.

7. The compound of claim 1 wherein the nicotine hapten
has a structure corresponding to:
13. The compound of claim 1 wherein the compound has
a structure corresponding to:

O-HBTU.
NH

O

NH-YKOGGFLGLYSFKPMPLaR.
NH
O

t

8. The compound of claim 1 wherein the nicotine hapten
has a structure Selected from the group consisting of
(a)

HOOC

CH

N
N

2

14. A vaccine composition comprising the compound of
claim 1.

15. A vaccine composition comprising the compound of
claim 4.

16. A vaccine composition comprising the compound of
claim 12.

(b)

17. A vaccine composition comprising the compound of
claim 13.

21

w

N

N-cool and

N
N

(c)

H2N

21
N

w

N

CH

9. The compound of claim 1 wherein the nicotine hapten
is linked to the molecular adjuvant by a Spacer moiety.

18. A method of treating nicotine addiction in a patient in
need of Such treatment, the method comprising administer
ing to the patient a therapeutically effective amount of the
compound of claim 1.
19. A method of treating nicotine addiction in a patient in
need of Such treatment, the method comprising administer
ing to the patient a therapeutically effective amount of the
compound of claim 4.
20. A method of treating nicotine addiction in a patient in
need of Such treatment, the method comprising administer
ing to the patient a therapeutically effective amount of the
compound of claim 12.
21. A method of treating nicotine addiction in a patient in
need of Such treatment, the method comprising administer
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ing to the patient a therapeutically effective amount of the
compound of claim 13.
22. A method of preventing nicotine addiction in a patient
in need of Such treatment, the method comprising adminis
tering to the patient a therapeutically effective amount of the
compound of claim 1.
23. A method of treating nicotine addiction in a patient in
need of Such treatment, the method comprising administer
ing to the patient a therapeutically effective amount of the
compound of claim 4.
24. A method of treating nicotine addiction in a patient in
need of Such treatment, the method comprising administer
ing to the patient a therapeutically effective amount of the
compound of claim 12.
25. A method of treating nicotine addiction in a patient in
need of Such treatment, the method comprising administer
ing to the patient a therapeutically effective amount of the
compound of claim 13.
26. A method of producing antibodies to a nicotine
hapten, the method comprising:

28. The method of claim 26 wherein said compound has
a structure corresponding to:

NH-YSFKPMPLAR.
NH

29. The method of claim 26 wherein said compound has
a structure corresponding to:
O

NH-YKOGGFLGLYSFKPMPLaR.

(a) immunizing an animal with an immunogenic effective

NH

amount of the compound of claim 1,

O

(b) isolating antibodies from the Sera of the animal; and
(c) recovering the isolated antibodies.
27. The method of claim 26 wherein the targeting ligand
of the molecular adjuvant of Said compound binds Specifi
cally to a C5a receptor and is Selected from the group
consisting of C5a and a peptide agonist analog of C5a
comprising the C-terminal ten residues of C5a.

'',
CH

N
2

N

